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2ABSTRACT
Fibroblast growth factor 23 (FGF-23) has recently been shown to be
involved in phosphate regulation and bone mineralization.  This study evaluated
the effect of FGF-23 on three human cell lines (Caco-2, HK-2, SaOS-2)
representing three different sites of phosphate regulation (small intestine, kidney
proximal tubules, and bone, respectively).  FGF-23 induced gene expression was
studied using Clontech human Atlas glass microarrays containing various
assortments of genes and by a custom designed oligo microarray containing
specific genes selected for their biological relevance to FGF-23’s potential
function.  FGF-23 induced differential gene expression in all three cell types,
suggesting that FGF-23 may be capable of acting on these three primary sites of
phosphate regulation.  Human small intestine-like endothelial cell line, Caco-2,
showed upregulation of several genes including parathyroid hormone receptors 1
and 2.  FGF-23 inhibited the expression of water channel transporters aquaporin 5
and 6 in human osteoblast-like SaOS-2 cells while upregulating aquaporin
expression in HK-2 cells.  Somatostatin receptors 1-4 were identified to be
upregulated in the human kidney, HK-2 cell line.  Mucin 2, a gene that is linked to
abnormal cellular growth, was consistently induced by FGF-23 in all three cell
lines.  Families of aquaporins, somatostatins, parathyroid hormones, and other
identified differentially expressed genes are involved in different signaling
pathways that are associated with phosphate and calcium regulation. Selected
candidates were analyzed further by real-time RT-PCR.  These data support FGF-
323 induced regulation of aquaporin 5 mRNA in HK-2 cells and 1aOHase mRNA in
Caco cells.  FGF-23 induced changes in mRNA analysis of four additional genes
was less than two-fold in triplicate analysis of selected samples.  Taken together,
these results suggest that each cell type may have responded to FGF-23, but
additional validation of the array data set will be required to identify those genes
specifically regulated by FGF-23.  Further refinement of this data set will
undoubtedly uncover additional functions of FGF-23 and may provide valuable
insight into designing therapeutic approaches for phosphate specific disorders.
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9BACKGROUND
Introduction
The maintenance of serum phosphate homeostasis is among the factors
important for basic cellular survival and is involved in vital biological processes
such as calcification of skeletal tissues, generation and transformation of cellular
energy, and modulation of protein activity (Broadus 99).  Phosphate dysregulation
is associated with several medical conditions that detrimentally affect patient
morbidity and mortality such as autosomal dominant hypophosphatemic rickets
(ADHR), X-linked hypophosphatemic rickets (XLH), oncogenic osteomalacia
(OOM) and end stage renal disease (ESRD).  Until recently, it was well accepted
that phosphate homeostasis is maintained by the calcitrophic hormones 1,25
dihydroxyvitamin D3  (1,25(OH)2D3) and parathyroid hormone (PTH), the same
hormones involved in calcium homeostasis.  This view was inconsistent with the
observation that under certain disease states (XLH, OOM, ADHR) serum
phosphate levels were abnormally low despite normal serum calcium
concentrations.  These symptoms cannot be explained by the known actions of
vitamin D and PTH.  Subsequently, increased serum levels of fibroblast growth
factor (FGF)-23 were found in individuals with ADHR (White et al. 2002), OOM
(Jonnson et al. 2002, Yamazaki et al. 2002) and XLH (Jonnson et al. 2002,
Yamazaki et al. 2002).  Recently, FGF-23 has been shown to specifically
modulate phosphate uptake without affecting net calcium homeostasis.  This
finding supports the hypothesis that a novel control mechanism exists whose
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primary function is to control phosphate.  Understanding FGF-23’s mechanism of
action may provide insight into this pathway as well as enable the development of
more effective phosphate regulating therapeutics, that eliminate the detrimental
calcium side effects associated with current therapies.
Fibroblast growth factor family
FGF-23 is a member of a large family of peptide factors (ADHR consortium
2000).  The FGF family consists of 23 distinct genes and five known receptors.
Knowledge of other FGF binding and signaling characteristics can be leveraged to
develop an understanding of FGF-23’s specific mechanism of action.  FGF family
members are associated with diverse vital functions throughout embryonic
development, cell proliferation, cell-survival activities, tissue repair, and tumor
growth.  Most FGFs contain a secretion signal sequence to allow for extracellular
localization and contain strong heparin binding domains that generally affect
signaling by modifying FGF binding specificity (Powers et al. 2000).  A core of 140
amino acids remains highly homologous throughout the FGF family.  These
conserved amino acids form 12 anti-parallel beta-strands that create a cylindrical
barrel, a defining feature of the FGF family (Zhang et al.1991).  It is this
topological similarity that unites the FGFs, not their biological function.  The
receptor binding interactions and the diverse functions of FGFs can be
appreciated by viewing table 1.
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Name Synonym(s) Signaling through high-affinity
receptors
Comments*
FGF-1 Acidic FGF,
aFGF
FGFR-1,IIIb &IIIc;FGFR-2,IIIb &
IIIc;FGFR-3,IIIb & IIIc; FGFR-4
Broad mitogenic and cell survival activities.
Involved in similar functions as FGF-2
FGF-2 FGF-2 Basic
FGF, bFGF
FGFR-1,IIIb &IIIc;FGFR-2,IIIc;
FGFR-3,IIIc;FGFR-4
embryonic development, cell growth,
morphogenesis, tissue repair, tumor growth
and invasion
FGF-3 Int-2 FGFR-1,IIIb;FGFR-2,IIIb Over expression results in abnormal prostate
and Wolffian duct development
FGF-4 kFGF, kaposi
FGF hst-1
FGFR-1,IIIc;FGFR-2,IIIc;FGFR-3,
IIIc;FGFR-4
Regulate cell number in the nascent limb bud
and are required for survival of cells located
far from the apical ectodermal ridge.  Similar
functions as FGF-8.
FGF-5 FGFR-1,IIIc;FGFR-2,IIIc Signal sequence
FGF-6 hst-2 FGFR-1,IIIc;FGFR-2,IIIc,FGFR-4 Signal sequence
FGF-7 KGF FGFR-2,IIIb Homologous rodent genes are implicated
with morphogenesis of epithelium, hair
development and early lung organogenesis
FGF-8 AIGF FGFR-1,FGFR-2,IIIc;FGFR-3,
IIIc,FGFR-4
7 isoforms, all with signal sequences.
Transgenic expression in mice induces
differentiation of pancreatic islet cells into
hepatocytes and exocrine cells
FGF-9 GAF FGFR-2,IIIc;FGFR-3,IIIb & IIIc,
FGFR-4
Expression of the mouse homologue was
found to be dependent on Sonic hedgehog
signaling.  Potential role in testicular
embryogenesis.
FGF-10 KGF-2 FGFR-1,IIIb;FGFR-2,IIIb Lunatic fringe, FGF, and BMP regulate the
Notch pathway during epithelial
morphogenesis of teeth.
FGFs 11 –
14
FGFs Unknown Associated with nervous system
development
Multiple isoforms exist
FGF-15 Unknown Gene is activated byE2A-Pbx1
FGFs 16 –
18
FGF-17;FGFR-1,IIIc;FGFR-2,IIIc may play a role in development of brown
adipose tissue, brain development and
stimulates hepatic and intestinal proliferation
FGF-19 FGFR-4 high affinity, heparin dependent ligand for
FGFR4
FGF-20
XFGF-20
XFGF-20 Unknown Sequence homology to FGF-9.  Expressed in
the brain and able to enhance the survival of
midbrain dopaminergic neurons in vitro.
FGF-21 Unknown Sequence homology to novel mouse FGF-
21, FGF-9
FGF-22 Unknown Sequence homology to FGF-10 and FGF-7
FGF-23 FGFR-2, FGFR-3, FGFR-4 associated with phosphate regulation
*Modified from Powers et al. (2000).
Table 1.  Functions of human FGFs. Fibroblast growth factors are involved in various functions and
pathways.
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Identification of human FGF-23
As shown in figure 1, FGF-23 is a 30 kDa secreted protein that is
processed by a pro-convertase type enzyme into two smaller fragments of
approximately 18 kDa (amino fragment) and 12 kDa (carboxy fragment).  The
biological activities of the intact, amino, and carboxyl fragments of FGF-23 have
not yet been delineated.  The wild type FGF-23 contains the pro-convertase site
and can be processed into two fragments in the presence of the enzyme.
Figure 1.  Pro-convertase processing of full length FGF-23.  A cleavage site at amino acid 176-179 (RXXR
motif) cuts the full length FGF-23 into two fragments.
Several independent groups identified FGF-23 utilizing distinct strategies.
Mouse FGF-23 was identified and cloned from a murine brain tissue cDNA library
and using a computer homology search, human FGF-23 was identified
(Yamashita et al. 2000).  At the time of discovery, these investigators had no
insight into FGF-23’s physiological function.  More recently, FGF-23 has been
shown to be expressed in OOM tumors, human heart, liver and thyroid/parthyroid
tissue by northern analysis (ADHR Consortium 2000, figure 2).  Sequence
comparisons show that FGF-23 is most similar to FGF-19 and FGF-21 (ADHR
18 kDa 12 kDa
Pro –
Conv
5’ 3’
3’5’ 3’
Full length FGF-23
Processed FGF-23
FGFR
Binding
Domain
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Consortium 2000).  The specific functions of FGF-19 and FGF-21 are not known
but they have not been associated with phosphate regulation.  FGF-23 is
significantly distinct from other FGFs in that it is the only family member to contain
a pro-convertase processing site.
Figure 2.  Sequence comparison between FGF-19, FGF-21 and FGF-23.  Both FGF-19 and FGF-
21 have a 26% identity homology to FGF-23.
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FGF-23 association to genetically inheritable diseases
Identification of FGF’s function arose from studies centered on a class of
hypophosphaturic and hyperphosphatmic disorders which included autosomal
dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemic rickets
(XLH) and oncogenic osteomalacia (OOM) (Table 2).  The kidneys of individuals
with these disorders have a reduced capacity to reabsorb phosphate that results
in phosphate wasting through urine exertion (i.e. phosphaturia).  Subsequently,
these individuals have low serum phosphate levels, (i.e. hypophosphatemia) due
to a reduced capability of the kidneys to reabsorb phosphate back into the blood
stream (Econs et al. 1997).  In order to maintain the proper phosphate serum
concentrations, the phosphate reservoir in bone is tapped.  As the phosphaturia
continues, the reservoir in the bone is depleted and the bone matrix strength is
compromised.  The bone is no longer capable of proper growth and
mineralization, and the result is poor skeletal integrity (Shore 1999).  Strikingly,
each of these individuals have normal levels of calcium and the two known
regulators of phosphate and calcium homeostasis; 1,25(OH)2D3 (the active form of
vitamin D) and parathyroid hormone (PTH).  As discussed below, recent evidence
has established a link between increased circulating levels of FGF-23 and each of
these disorders.
Table 2.  Clinical evidence that calcium homeostasis is maintained in patients with
hypophosphatemia.  Serum phosphate levels are low while calcium is maintained through
PTH and vitamin D activity.
Clinical Features XLH ADHR OOM
Serum phosphate Low Low Low
Serum calcium Normal Normal Normal
1,25(OH)2D3 Low/normal Low Low/Normal
25(OH)D3 Normal Normal Normal
PTH Normal Normal Normal
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The correlation between FGF-23 and ADHR was established by statistical
genetic analysis.  A large lod score to the ADHR pedigree, a value of 7.68 (ADHR
consortium 2000) helped to identify a region on chromosome 12 that was most
likely to contain specific mutations responsible for ADHR.  A lod score analysis is
a statistical determination of events occurring at random chance.  A small lod
score suggests that there is little or no linkage between the events in question
while a high lod score represents a statistical association and suggests that there
may be a biological association.  Using a positional cloning approach on the
region identified by the lod score analysis, the ADHR Consortium identified a
specific site within a novel gene they named FGF-23 to be associated with the
genetic disorder.  Sequence analysis revealed that all ADHR individuals contain a
mutation within a 12 base pair region of the 251 FGF-23 amino acid coding
sequence that were not found in unaffected individuals.  Interestingly, the mutated
region (positions 176-180) encodes a motif site (RXXR) that is sensitive to
endopeptidase cleavage by a pro-convertase.  This raised the possibility that
failure to process FGF-23 during its synthesis alters FGF-23 activity.  As
described below, it is now believed that this activating mutation is responsible for
elevated levels of biologically active circulating FGF-23 by somehow stabilizing
FGF-23, by preventing cleavage and, in turn, inhibits reabsorption of phosphate
from the kidney into the blood resulting in phosphate wasting (White et al. 2001).
The association of the identified FGF-23 mutations to phosphate dysregulation
and their association to ADHR are among the contributing factors that lead to the
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desire and need to elucidate the properties of FGF-23.  ADHR belongs to a class
of hypophosphatemic disorder that includes OOM and XLH.
Evidence of FGF-23 association with a tumor induced hypophosphatemia
In addition to ADHR, FGF-23 has also been associated with a tumor-
induced phosphate wasting disorder, oncogenic osteomalacia (OOM).  Like
ADHR patients, these individuals have low serum phosphate levels, low/normal
1,25(OH)2D3 (active form of vitamin D) and osteomalacia.  Upon excision of the
tumors, patient’s serum phosphate levels return to near normal and bone
mineralization resumes (Kumar et al., 2000) suggesting that the tumor was
responsible for the phosphate wasting disorder.  Three groups independently
linked the overexpression of human FGF-23 to OOM (White et al. 2001, Shimada
et al. 2001, Jan de Beur et al. 2002).  White et al. (2001) verified that FGF-23 was
a secreted protein by Western blot analysis of sera.  Shimada et al. (2001) used a
differential expression cloning strategy to identify cDNA clones representing
abundantly expressed OOM tumor genes that were not expressed in normal
tissue adjacent to the tumor.  Wild type FGF-23 was among the identified
candidates.  Independent of Shimada’s work, SAGETM (Serial Analysis of Gene
Expression) was used to identify genes of high expression levels in OOM tumors
compared to histologicaly matched control tumors that did not induce phosphate
wasting.  FGF-23 was identified as one of several candidates over expressed
within OOM tumors (Jan de Beur et al. 2002).  SAGETM is unique to other gene
quantification technologies because it does not require knowledge of the gene
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sequence prior to quantification and hence allows for identification and
quantification of novel genes.  In SAGE analysis, a concatamer of 10-14
oligonucleotide tag representing each gene transcript is constructed, sequenced
and quantified.  The identified 10-14 oligonucleotide fragment is compared to
databases to identify the corresponding gene.  The association of FGF-23 to two
phosphaturic conditions, OOM and ADHR provided strong evidence linking the
function of this gene to phosphate regulation.
FGF-23 association to X-linked hypophosphatemia
Similar to ADHR, X-linked hypophosphatemia (XLH) is another genetically
inheritable medical condition that induces phosphate wasting (Meyer et al. 1989).
XLH patients have biochemical and clinical features similar to ADHR.  Figure 3
shows the classic leg deformities often found in XLH and ADHR patients.  Low
serum phosphate levels result in poor bone mineralization and classic bowing of
the legs.  OOM patients who acquire tumors later in life suffer from osteomalacia
but do not have bowing of the legs.
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Figure 3.  An illustration of bone deformation in children suffering from x-linked
hypophosphatemia.  Due to poor bone mineralization, structural integrity is weakened resulting on
poor growth and bowing.
 In XLH, ADHR, and OOM, elevated serum levels of biologically active
FGF-23 are observed in most patients but the dysregulation of FGF-23 in XLH
occurs in a different manner (HYP Consortium 1995).  XLH patients have a
mutated membrane bound endopepidase, PHEX (Phosphate regulating gene with
homology to Human Endopeptidase on the X chromosome).  PHEX is a member
of a family of homologous endopeptidases, many of which have been shown to
control the activity of peptide factors by cleavage.  Bowe et al. (2001)
demonstrated that FGF-23 may be degraded by PHEX with a crude in vitro assay.
Using recombinant human secreted PHEX, an in vitro assay was used to identify
a consensus PHEX cleavage site (Boileau 2001).  Coincidentally, this motif is
present within the carboxyl fragment of FGF-23 (figure 4).  These results are
consistent with the hypothesis that the inactivating PHEX mutation protects FGF-
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23 from degradation, which results in elevated levels of FGF-23 that, in turn,
causes phosphate wasting.
The results of the Bowe et al. (2001) study was challenged by Guo et al.
(2001).  These investigators were unable to demonstrate that mouse recombinant
PHEX cleaves a 14 amino acid peptide representing a fragment of human FGF-23
that contains the putative PHEX cleavage site.  They suggest that FGF-23 is not a
substrate for PHEX but that FGF-23 may be involved in a more complex model
where FGF-23 may alter the production of the true PHEX substrate or alter the
activity of PHEX.  However, their results may also be explained if a PHEX-
mediated cleavage of their FGF-23 peptide was not observed due to the absence
of additional required recognition sites located outside the small 14 amino acid
fragment used in their experiment.  Furthermore, it is unlikely that the detection
method used in this study would have distinguished the predicted cleavage
product from the intact peptide.
Figure 4.  Illustration of PHEX mediated regulation of FGF-23 activity via an initial pro-convertase
cleavage at the furin processing site.  A pro-convertase cleaves FGF-23 into two fragments at the
furin cleavage site and subsequently PHEX is capable of modulating FGF-23 activity.
Furin
PHEX
N terminus C terminus
5’ 3’
3’5’ 3’
5’ 3’
N terminal
fragment
Full length FGF-
Active FGF-23
Active fragment
PHEX mediated
FGF-23 activity
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Summary of phosphate dysregulation
XLH, OOM and ADHR cause a dysregulation of phosphate homeostasis
resulting in hypophosphatemia that can lead to bone defects even though calcium
homeostasis is maintained.  Figure 5 illustrates a proposed model explaining the
link of FGF-23 to all three phosphate wasting disorders.
Figure 5.  Summary of three medical conditions, OOM, XLH, ADHR, that all result in elevated
serum levels of FGF-23 and phosphate wasting.  (Schiavi and Moe 2002)
Under normal conditions FGF-23 activity may be negatively regulated by PHEX.
In OOM, FGF-23 is produced in such excess that FGF-23 levels or activity can not
be modulated.  In XLH, the defective PHEX is unable to cleave and inactivate
FGF-23.  Specific mutations render FGF-23 resistant to processing by a yet
unidentified pro-convertase enzyme within individuals with ADHR.  As PHEX
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prefers small molecular weight substrates, it has limited access to the intact non-
processed mutant FGF-23 protein.  In all the cases, FGF-23 is abundantly and
detrimentally available to disrupt phosphate homeostasis.  This hypothesis is
supported by the recent findings that circulating levels of FGF-23 are elevated in
most patients with XLH, ADHR, and OOM (Jonnson et al., 2002, White et al.
2002, Yamazaki et al. 2002)
FGF-23 is a phosphate regulating hormone
Linkage of FGF-23 over expression with diseases of phosphate
dysregulation suggested a role in phosphate regulation.  FGF-23 assayed in
subsequent in vivo and in vitro studies demonstrated that FGF-23 could directly
regulate phosphate (Bowe et al. 2001, Yamashita 2002, et al. 2002, Shimada et
al. 2002).  The major site of phosphate regulation is in the kidney.  Approximately
80% of phosphate that is filtered into the kidney is reabsorbed and released back
into the blood stream through specific phosphate transporters called the type IIa
sodium phosphate transporter (NaPi IIa) (Murer and Biber 1996) (Figure 6).  NaPi
IIa is primarily expressed in the brush border membrane of the renal proximal
tubules.  The microvilli that express NaPi IIa are located on the apical surface of
the tubule.  Under normal conditions, if serum phosphate is high, the kidney
reabsorbs less phosphate and a greater percentage of phosphate is excreted as a
waste product.  In the diseased conditions described above, patients have low
serum phosphate levels and elevated levels of phosphate in the urine.  This
scenario raised the possibility that FGF-23 could exert specific actions on the
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kidney’s control of phosphate.  Thus, initial studies have examined FGF-23’s
ability to regulate phosphate secretion/reabsorption in appropriate in vitro and in
vivo models.
In vitro studies have demonstrated that FGF-23 inhibits phosphate uptake
in opossum kidney (OK) cells, a cell line derived from renal proximal tubule cells
that continues to express NaPi IIa (Bowe et al. 2001, Yamashita et al. 2002).  The
OK cell assay is the classic method of measuring the PTH mediated effect on
phosphate uptake.  Bowe et al. (2001) developed an optimized assay to measure
FGF-23 mediated effects.  Both wild type and ADHR mutant forms of FGF-23 can
produce up to a 60% reduction in phosphate uptake.  The in vitro role of FGF-23
in phosphate transport provides a possible explanation for hypophosphaturia in
OOM patients by reduced renal phosphate reabsorption in the kidney.  From the
in vitro OK assay we know that FGF-23 modulates phosphate uptake.  Since
human FGF-23 biologically affects opossum kidney cells, it is likely that human
kidney cells are also responsive, especially with the clinical evidence linking FGF-
23 to phosphate wasting in OOM, ADHR and XLH patients.  Additionally, non-
published data by Stephen O’Brien (Genzyme Corp.) has demonstrated that FGF-
23 causes internalization of the NaPi IIa transporter, making it no longer
accessible at the membrane, suggesting a mechanism by which FGF-23 could be
blocking reabsorption of phosphate.
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Figure 6.  Illustration of phosphate regulation in the kidney.  Tubules within the kidney contain
NaPi IIa transporters that reabsorb phosphate (Pi) from the urine back into the blood stream.
In vivo experiments also demonstrate that FGF-23 has a role in phosphate
regulation.  Mice dosed three times in a ten hour period with recombinant FGF-23
exhibited phosphate wasting.  Serum 1,25(OH)2D3 serum levels were low
whereas serum calcium  and PTH concentrations were unaffected (Shimada et
al., 2001, Shimada  ASN 2002).  Nude mice implanted with FGF-23 expressing
CHO cells (Shimada et al. 2001), and transgenic FGF-23 knock-in mice (Shimada
ASBMR 2001) have profound hypophosphatemia and low circulating levels of
1,25(OH)2D3.  In addition, a significant decrease in bone density was observed in
the transgenic compared to control animals at 45 days (figure 7).  FGF-23
knockout mice show clinical symptoms of hyperphosphatemia and increased
serum 1,25(OH)2D3  concentrations (Shimada, ASN 2002).  Taken together, these
TubuleKidney Endothelialcells
Epithelial
cells
Pi
Urine Blood
NaPi 2A
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in vitro and in vivo results indicate FGF-23 plays an important role in controlling
phosphate regulation.  Furthermore, in vivo studies also suggest that FGF-23
plays a role in the regulation of the vitamin D pathway.
Figure 7.  X-ray image of mouse implanted with CHO cells that over express FGF-23 compared to
control.  Mice exposed to higher than normal levels of FGF-23 have a lower bone density
compared to control (Shimada et al. 2001).
Mineral Homeostasis
The intestine, kidney, and bone are the primary sites for mineral exchange.  The
minerals ingested are absorbed through the small intestine, secretion is
modulated through reabsorption in the kidney, and the bone is utilized as a
reservoir for rapid availability of the necessary minerals.  Calcium, phosphorous,
and magnesium are the three most abundant minerals that require constant
regulation to maintain a proper balance of circulating and intracellular
concentrations necessary for normal biological functions.  The finding that a novel
hormone exists that appears to regulate phosphate levels without causing net
changes in calcium is a major advance in our understanding of mineral
Control
Elevated
FGF-23
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homeostasis.  Prior to the discovery of FGF-23, it was assumed that phosphate
regulation occurred as a secondary action of PTH and Vitamin D3.
The primary role of PTH and 1,25(OH)2D3 (active form of vitamin D) is to
maintain calcium homeostasis (Figure 8a).  Secretion of PTH occurs in response
to low circulating levels of calcium.  PTH increases re-absorption of calcium in the
kidney while reducing re-absorption of phosphate in the kidney.  Elevated levels of
PTH increase the synthesis of 1,25(OH)2D3 by activating the key catabolic
enzyme 1-alpha-hydroxylase (1aOHase) that converts the inert vitamin D
(25(OH)D3) into the active state of 1,25(OH)2D3.  An elevated level of 1,25(OH)2D3
increases intestinal absorption of calcium and phosphate and mobilization of
calcium and phosphate from bone stores leading to a normalization of calcium.
Thus, these two hormones represent a cyclic feedback system to control calcium
and phosphate.
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Figure 8a.  Ca+ 2 homeostasis via activity of PTH.  Low Ca+ 2 in the extracellular fluid (ECF),
mediates stimulation of PTH and the subsequent increase in 1,25OH2D3 resulting in an increased
serum Ca+2 by action on the intestine, kidney and bone while Pi wasting is increased through the
kidney. Red arrow (low Ca+ 2) initiates the cellular response, green arrows indicate what PTH act
on, black arrows represent the subsequent mineral change.
Figure 8b.  The effect FGF-23 on PO4 in the extracellular fluid (ECF).  Evidence suggests that
FGF-23 can directly act on the kidney and may modulate 1aOHase to possibly reduce
1,25(OH)2D3 levels.  It is uncertain whether FGF-23 can act directly on the small intestine or on the
bone but the net effect is phosphate wasting through the kidney. It is uncertain what regulated
FGF-23 but in vivo data suggest inhibitory action on 1aOHase solid red arrow, and subsequent
potential inhibitory action in the intestine and bone (dotted red line).  Green arrows indicate
positive regulation of PO4 wasting through the kidney.  Black arrows represent the subsequent
mineral change. Dotted lines and ? indicate uncertain action.
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   FGF-23 and PTH appear to have some overlapping and some divergent
functions.  Both enzymes regulate phosphate reabsorption through the type IIa
sodium phosphate transporters in the kidney.  In contrast, PTH upregulates
1aOHase expression whereas FGF-23 represses 1aOHase expression.  Thus the
two hormones appear to differently control 1,25(OH)2D3.  It is not yet clear how the
body responds to the actions of these two separate hormones and why there is a
need to control 1,25(OH)2D3 independently from phosphate.  There are currently
no indications that FGF-23 effects PTH levels or vice versa.
Sites of action for phosphate regulation
FGF-23 is a regulator of phosphate homeostasis.  A key question is
whether FGF-23 can act at other primary sites for phosphate regulation.  Net
circulation levels of phosphate are also influenced by regulation at the small
intestine and the bone.  The bone acts as a reservoir to supply phosphate to the
circulatory system as needed to maintain homeostasis.  The kidney, as discussed
above, regulates the excretion rate of phosphate by modulating reabsorption of
phosphate back into the circulatory system whereas entry of phosphate into the
body is controlled by absorption in the intestine.  In addition to these global
regulatory actions of systemic phosphate concentrations, there are likely local
control mechanisms that allow independent cells to regulate phosphate entry.
FGF-23 may also play a role here.  Local phosphate regulation must vary a little
because the expression patterns of the phosphate transporters differ between cell
types.
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There are three members of the Na+-dependent Pi cotransporter family.
NaPi-1 was the first to be cloned (Werner et al. 1991) but the specific
physiological and functional role is still not certain (Werner et al. 1998).  NaPi II
has three isoforms.  NaPi IIa and IIc are renal specific.  Approximately 80% of
renal phosphate transport occurs through NaPi IIa.  NaPi IIb is located primarily in
the intestine.  The third family member of the Na+ dependent Pi cotransporter is
NaPi-3.  NaPi-3 cotransporter expression can be detected in osteoblast-like cells
and may be important in the control of uptake during bone mineralization.  The
NaPi-III transporters are ubiquitously expressed and may be important targets
controlling local changes or requirements for phosphate.  NaPi  III transporter
function has also been implicated in the process of bone mineralization (Nielsen
et al. 2001).
As previously discussed, FGF-23 is a secreted factor (White et al. 2001)
which allows FGF-23 to have both systemic and localized effects.  FGF-23 has
been shown to have binding specificity for three of the five known FGF receptors
(Yamashita et al. 2002; Pragnell, Genzyme Corp.).  As expression patterns of
NaPi transporters vary among cell types, so does the expression patterns of FGF
receptors.  As shown below, the known receptors that bind with FGF-23 are
expressed in cell types representing the three sites of phosphate regulation.
Therefore it is possible, but not yet demonstrated, that FGF-23 may affect
phosphate transport in the large intestine and bone.
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FGF receptors
The 23 known FGFs are believed to induce their specific signaling by
binding to one or more of the four functional membrane bound receptors, FGF
receptor 1-4 (FGFR) (Powers et al, 2000).  A fifth receptor (FGFR-5) has been
identified but it is not believed to transmit a signal since it lacks a classic
cytoplasmic signaling domain (Kim et al. 2001).  Although the possibility of the
FGFs interacting with novel receptors exists, none have been identified.  FGFRs
contain three immunoglobin (Ig)-like repeats.  It is likely that the homophilic
characteristics of these Ig-like domains (Dackowski et al. 2002) within the
extracellular domain of the FGFR promote dimerization of the membrane bound
receptor.  The extracellular portion of the receptor interacts with the FGF ligand,
initiating the signaling cascade (Wiedemann and Trueb 2001).  Every FGFR has a
single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine
kinase domain.  FGFR’s 1-4 have 18-29 exons in each gene resulting in multiple
splice variants which helps to explain how 23 FGF ligands can have only four
functional receptor genes.  For example, the gene that codes for FGFR-1
encompasses 19 exons that allows for complex alternative splicing which may
affect ligand affinities to the receptor (Johnson et al. 1991).  Although the manner
by which FGFR expression is regulated within a cell type is not completely
understood, it is possible that the alternative splicing may influence the functional
expression of a receptor.  This mechanism could account for the receptor
expression differences among various types of tissues.  In addition to the tissue
type, the proliferative state of an osteoblast-like cell, SaOS-2, has been shown to
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influence receptor expression profiles (Bilbe et al. 1996).  Multiple isoforms and
variable expression of FGF receptors and FGF ligands partially explains how 23
FGF family members can specifically signal through only four receptors.
Receptor mediated signaling by FGFs is also modulated by heparin sulfate
proteoglycans (Pellegrini 2001).  Classic heparin involvement in FGF signaling is
associated to receptor dimer formation necessary for binding and signaling.  FGF-
23 contains heparin binding domains which suggests that heparin may directly
interact with the structural conformation of the protein as well as during receptor
dimerization.
FGF-23 signaling pathway
In vitro binding studies have shown that FGF-23 binds to FGFR-2, FGFR-3,
and FGFR-4 (M. Pragnell, Genzyme Corp., personal communication).  Yamashita
et al. (2002) also found that FGF-23 binds to FGFR 2 and a splice variant of
FGFR-3, FGFR-3c using in vitro Biacore binding studies.  This study did not
investigate the specificity or relative affinities of these interactions, nor did it
investigate binding to FGFR4.  Yokote (2002 ASBMR) has shown the expression
of FGFR-2 and FGFR-4 but not FGFR-1 or FGFR-3 in opossum kidney cells, the
most responsive cell line to PTH and FGF-23.  Their studies suggest that FGF-23
signals through FGFR-2 and not FGFR-3c.  Recent FGF-23/receptor binding
studies suggests that heparin strongly affects binding specificity and activity
(Pragnell and Bowe, Genzyme Corp., unpublished observations).  Conflicting
evidence exists suggesting heparin my inhibit (Bowe et al., 2001 or activate FGF-
31
23’s ability to modulate phosphate transport (Yamashita et al., 2002).  Further
work is required to better understand the role of heparin.  However, it is possible
that differential expression of specialized heparan proteoglycans within various
subclonal lines of OK cells may account for variable efficacy of FGF-23efficacy in
the opossum phosphate uptake assay.
It is unclear which receptor(s) is physiologically relevant but current studies
agree that a known FGFR is likely to be involved in the initiation of the tyrosine
signaling cascade.  SU 5402 is an inhibitor for tyrosine kinases of the FGF
receptors.  SU 5402, blocks the activity of FGF-23 and subsequently enables
phosphate uptake in an in vitro opossum kidney cell assay with the presence of
FGF-23 was also shown (Yamashita et al. 2002).  Evidence for FGF-23 induced
tyrosine phosphorylation event has also been confirmed at Genzyme (S. O’Brien,
personal communication).
To date only limited studies have investigated FGF-23 regulation of gene
expression.  In vivo studies have demonstrated that FGF-23 may reduce mRNA
and protein expression of 1aOHase at specific time points post treatment and that
type IIa sodium phosphate transporter proteins appear to be post-transcriptionally
modified (Shimada, 2001 ASBMR abstract).  How FGF-23 elicits these effects is
not known.  Additional FGF-23 regulated genes haven not yet been identified.
 It is assumed that FGF-23 may regulate gene expression similarly to other
family members.  The binding of FGFs to FGF receptors triggers an
autophosphorylation cascade and recruitment of phospholipases such as C-
gamma and Crk. Tyrosine phosphorylation promotes associations of SNT1/FRS-2
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docking proteins to FGF receptors.  These docking proteins activate Ras that in
turn activates the Raf-MEK-mitogen-activated protein (MAP) kinase pathway
(Park et al. 2002).  Ultimately, transcription factors such as Jun, Fos, and Myc are
phosphorylated and gene transcription is further modulated.
Potential transcriptional regulation by FGF-23
This work is focused on developing a better understanding of FGF-23
induced gene transcription by monitoring transcription levels of thousands of
genes using microarrays.  Ultimately, the identity of the genes shown to be
differentially expressed in response to FGF-23 will be used to infer potential
functions of FGF-23 and to determine if the functions are consistent or variable
across different sites of phosphate regulation.
Using Serial Analysis of Gene Expression (SAGE), OOM tumors were
shown to over express genes involved in bone matrix formation, ion transport,
phosphate homeostasis and mineralization (Jan de Beur et al., 2002a).  Genes
relevant to phosphate homeostasis included two phosphate regulating factors,
FGF-23 and frizzled related protein 4 (FRP-4) and the type III sodium phosphate
transporter, Glvr1.  Due to the large localized concentration of FGF-23 within the
tumors, it is possible that FGF-23 may generate an autocrine effect and induce
expression of additional genes.  Thus, at least a portion of the differentially
expressed genes in the OOM tumors represent genes induced directly by FGF-
23.  It is also important to point out that several additional cytokines, including
transforming growth factor beta (TGF-b), insulin-like growth factor II (IGF-II)  and
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connective growth factor (CTGF), were over-expressed in the OOM tumors.  Thus
it is likely that these factors may also have participated in the upregulation of
some of the OOM associated genes.  To further explore genes of particular
biological interest, a custom array was designed and generated which contains
about 200 genes.  Genes were selected based on their previously identified
association to OOM tumors by SAGE analysis and/or literature searches of genes
involved in phosphate regulation or bone metabolism.  In an effort to monitor the
maximum number of genes that may be affected by FGF-23, commercial arrays
containing 7,200 unique genes were used to analyze samples.
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PROJECT PURPOSE
The major goal of this project was to verify that FGF-23 could have a
biological effect on the cell lines, Caco-2, HK-2, and SaOS-2, representing the
three primary sites of phosphate regulation in the body (small intestine, kidney
and bone, respectively).  The second goal was to identify specific genes that were
regulated by FGF-23 within each cell type and to determine if similar genes were
affected across different cell types.  We were also interested in learning if FGF-23
was acting as an autocrine factor and upregulating genes identified in the OOM
tumor SAGE analysis.  The overall goal was to develop a better understanding of
how FGF-23 disrupts phosphate homeostasis.
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ABBREVIATIONS
25(OH)D3 pre-active form of vitamin D, 25-dihydroxyvitamin D3
1aOHase 1-alpha-hydroxylase vitamin D activating enzyme
1,25(OH)2D3 1,25-dihydroxyvitamin D3, active form of vitamin D  via 1aOHase
24OHase  25-hydroxyvitamin D-24 hydroxylase, vitamin D inactivating enzyme
1,24,25(OH) 2D3 degraded form of active vitamin D via 24-hydroxylase
ADHR autosomal-dominant hypophosphatemic rickets
FGF fibroblast growth factor
FRP frizzled-related protein
PTH parathyroid hormone
OOM tumor- oncogenic osteomalacia
XLH X-linked hypophosphatemia
HK-2 human kidney 2 cells
SaOS-2 Homo sapiens osteosarcoma cells
Caco-2 colorectal adenocarcinoma
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METHODS AND MATERIALS
FGF-23 purification
E. coli strain BL21 cells containing the PCR2.1-T7-CT-Taq FGF-23
expression vector (constructed by Finnegan (Genzyme Corp.)) were provided by
Pragnell (Genzyme Corp).  These cells express intracellular FGF-23 containing a
carboxyl terminus histidine tag to aid in purification on a talon column and for
immunoblot detection via anti-V5 antibody (Invitrogen Cat# 46-0708).  50 ml of LB
media containing 50mg/L ampicillin was inoculated and grown for 8 hrs.  A 50 ml
culture was expanded to 4 liters of LB media with 50mg/L ampicillin and grown
overnight at room temperature.  Media was centrifuged at 4,500 relative
centrifugal force (rcf) for 15 minutes to generate bacterial pellets.  Pellets were
stored at -80°C until purification.  Pellets were thawed on ice with the addition of H
buffer (Buffer H: 50 mM NaPhosphate, 500 mM NaCl, 5 mM Imidazole, 1%
glycerol, 0.1% Ipegal pH 7.0, 2 tablets of protease inhibitor per 50 ml buffer Roche
Cat# 1873580) and vortexed to produce a cell suspension.  Bacterial pellets were
sonicated and insoluble bacterial cellular debris was removed from the lysate by
centrifuging at 10,000 rcf for 15 minutes.  The cell lysate containing solubilized
FGF-23 was incubated with Talon beads (Clontech Cat# 8901-4) at room
temperature, washed twice for 5 minutes with 10 ml H buffer and once with 100 ml
I buffer (Buffer I: 50 mM sodium phosphate, 500 mM NaCl, 5 mM Imidazole pH
7.0).  FGF-23 was eluted in 1 ml fractions using imidazole elution buffer
37
(Imidazole elution buffers: I buffer with the addition of 3M imidazole stock pH 7
diluted to 50 mM, 150 mM, 300 mM, 600 mM and 1 M).  Elution fractions were
analyzed by a coomassie stained tris glycine electrophoresis.  Fractions
containing FGF-23 of the appropriate size were pooled.  Pooled fractions were
diluted with H buffer to a final concentration of 150 mM immidozole and placed
over a second column to obtain greater purity.  The column was washed again as
previously described and eluted.  Eluted fractions were analyzed on coomassie
gels and by immunoblot.  Selected fractions containing high concentrations of
FGF-23 with minimal contaminants were pooled, supplemented with 0.1% BSA
(Sigma Cat# A-8918) and dialyzed into PBS (Gibco Cat# 20012-027).  FGF-23
purity was evaluated with coomassie gel, immunoblot analysis and quantified by
an anti-V5 antibody ELISA assay.  The anti-V5 antibody ELISA assay, specific to
the V5 tag on the wild type FGF-23, was developed and processed by Matijevic
(Genzyme Corp.).
Immunoblot analysis
A 10 ml sample of the FGF-23 elution fraction was electrophoresed using a
4-12% gradient NuPage Bis Tris gel (Invitrogen NP 0321) and 1 X NuPage MOPS
SDS running buffer (Invitrogen, Cat# NP 465025).  The protein was transferred to
a PVDF membrane (Bio-Rad, Cat# 162-0174) using a Bio-Rad Semi-Dry transfer
system.  A 1X transfer buffer containing 20% methanol, 48 mM Tris and 39 mM
glycine was used to transfer the protein from the Bis-Tris gel to the PVDF
membrane for 20 minutes at 0.5 Amps.  The PVDF membrane was blocked for 30
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minutes in buffer containing 5 g dried milk per liter phosphate buffered saline
(PBS).  PVDF membrane was washed twice with PBS containing 0.05% Tween-
20.  The PVDF membrane was transferred into 10 ml blocking buffer containing
1:5000 diluted (2 mg) anti-V5-HPR antibody (Invitrogen Cat# R900-50) and
incubated at least 1 hour at room temperature with gentle agitation.  The PVDF
membrane was washed twice with PBS containing 0.05% Tween-20.
SuperSignal West Pico (Pierce Cat# 34080) was used for chemiluminescent
detection.  Kit provided peroxide solution and luminol/enhancer solution was
mixed at a 1:1 ratio with a final volume of 3 ml.  The PVDF membrane was
incubated for 5 minutes, the excess reagent drained and the PVDF membrane
was exposed for 10 seconds to X-ray film (Kodak Cat# 165-1579) in a dark room.
X-ray film was developed using a Kodak M35A X-OMAT processor.
Cell cultures
HK-2 (HTB-37), Caco-2 (CRL-2102), and SaOS-2 (HTB-85) cell lines were
purchased from American Type Culture Collection (ATCC) and grown according
to recommended guidelines.  The human kidney proximal tubular cell line, HK-2
was grown in Keratinocyte SFM (Gibco Cat# 10724-011) with 5 ng/ml
recombinant epidermal growth factor (Cat# 10450-013) and 0.05 mg/ml bovine
pituitary extract (Cat# 13028-014).  Cells were grown in minimum essential
medium Eagle (ATCC Cat# 30-2003) with 2 mM L-glutamine, Earle's BSS with 1.5
g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium
pyruvate, 50 I.U./ml penicillin and 50 mg/ml strepomycin (Gibco Cat# 15140-122),
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and 20% fetal bovine (Gibco Cat#16000-044).  Caco-2 cells were originally
isolated from a primary colonic tumor and posses a large intestine phenotype prior
to differentiation.  For these studies Caco-2 cells were induced to differentiate into
a small intestine phenotype by maintaining the culture at 100% confluence for 10
days while fresh media was replenished 2-3 days (Mariadason et al. 2000).
SaOS-2 cells are osteoblast-like cells grown in DMEM/F-12 (Gibco Cat# 11330-
032), 50 I.U./ml penicillin, 50 mg/ml strepomycin (Gibco Cat# 15140-122), and
10% fetal bovine serum.  An SaOS-2 subclone (provided by Ann Bowe, Genzyme
Corp) designated as G4A, was selected for array analysis because these cells
were isolated based on their ability to maintain mineralization capacity.  All cell
lines were grown at 37°C in humidified air containing 5% CO2.
Treatment of cells with FGF-23
Each cell line was expanded to eight T-160 flasks.  48 hours prior to FGF-
23 treatment, fresh media containing 0.5% fetal bovine serum was added to the
cells.  SaOS-2 and HK-2 cells were near 70% confluence and Caco-2 cells had
been maintained at 100% confluence for 7 days at the time of FGF-23 treatment.
The recommended media for each cell line, with 0.5% FBS, was given to control
cells at time zero, and corresponding media supplemented with 50 ng/ml FGF-23
was given to the test samples.  At 24 hr, the media was removed from two control
T-160 flasks and two FGF-23 treated flasks, cells were washed once with PBS
and cells were then harvested after trypsinization (Gibco Cat#15050-065).  Cells
treated for a total of 72 hours were given the appropriate fresh media at 24 hour
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and 48 hr.  Following trypsinization, the cells were centrifuged at 3,000 rcf for 5
minutes, supernatant was removed, the cell pellets were flash frozen on dry ice
and stored at –80°C until RNA isolation.  The cells treated for 72 hours were
harvested in a similar fashion as the 24 hour samples and stored at –80°C.  Both
SaOS-2 and HK-2 cells were less than confluent at the time of harvest.
RNA isolation
Cell pellets from two T-160 flasks, approximately 40 million cells (40X106)
stored at -80°C were processed with Qiagen RNeasy Midi kit (Cat#74104).  Lysis
buffer (RLT) containing b -Mercaptoethanol (b-ME) was used to resuspend cells.
To ensure complete lysis, cellular homogenate was processed with Qiasheader
columns (Qiagen Cat# 79654).  The midi kit protocol was followed with the
addition of the recommended DNase treatment.
RNA gel electrophoresis
RNA was quantified by spectrophotometry (Beckman DU-600) at 260nm.
260nm/280nm ratios were above 2.0 for all samples.  RNA integrity was
determined by visualizing non-degraded 28S and 18S bands on denaturing RNA
gels.  1% denaturing agarose gel contained 82.5 ml of water, 10 ml of 10X MOPS
buffer and 7.5 ml of 12.3 M formaldehyde.  1X MOPS (Amresco Cat# E526)
running buffer was used for electrophoresis.  2 mg of total RNA was loaded with
denaturing RNA loading solution containing 45 ml 12.3 M formaldehyde, 45 ml 1 M
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formamide, 10 ml 10X MOPS buffer (0.4 M MOPS pH 7.0, 0.1 M NaOAc pH 7.0,
10 mM EDTA pH 7.0), 3.5 ml (10 mg/ml) ethidium bromide 0.4 mg/ml, 1.5 ml 0.1M
EDTA (pH 7.5) and 8 ml bromophenol blue dye (in 50% glycerol).  Samples were
heated at 70°C for 10 minutes and cooled on ice before loading onto the gel.
RT-PCR
RNA was isolated using Qiagen RNeasy kit as described above.  FGF-23
is believed to signal through FGF receptors.  Receptor mRNA expression profiling
was completed on the four known functional fibroblast growth factor receptors
(FGFR-1  (Accession number NM_015850), FGFR-2 (Accession number
NM_022969), FGF-3 (Accession number NM_022965), FGFR-4 (Accession
number L03840)) to provide a preliminary indication that the cell lines will be able
to respond to FGF-23 treatment.  GAPDH (Accession number AK026525) was
assessed as a positive control.  Forward and reverse PCR primers were designed
using the Primer Express software program (PE Applied Biosystems).
Thermocycling Tm was designed to be near 60°C and PCR products to be about
340 basepairs (bp) in size.  Primers designed for FGF receptor profiling are
shown in table 3.
Table 3.  Forward and reverse PCR primers for amplification of FGFR 1-4 and GAPDH.
Gene
name
Amplicon
size
Forward primer 5’-3’ Reverse primer 5’-3’
FGFR-1 370bp TTTGCCTTCACCCATAAGCC ACCAGGAGCATCTTACCCGAT
FGFR-2 330bp TGGCCTTCTGCTTCTGAGTTG CGGCTATTGCAAAGTGACTGG
FGFR-3 320bp GTGTGCAGGTTCCGATGTT AACAAAATCGCACCTGCC
FGFR-4 360bp TGACACAGTGCTCGACCTTGA CATTTGCTCCTGTTTTCGGC
GAPDH 226bp GAAGGTGAAGGTCGGAGT GAAATCCCATCACCATCTTC
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Applied Biosystems Taqman EZ RT-PCR kit (Cat# N808-0234) was used
to generate oligo d(T)16 primed cDNA in the reverse transcriptase step from 200
ng of total RNA template per sample.  Invitrogen PCR super mix (Cat# 10572-
014) was used to generate PCR reaction mix.  50 ml reaction was set up
containing 200 nM final concentration of forward and reverse primer.  1 minute
denaturing at 94°C was followed by 30 cycles of 94°C for 30 seconds, 60°C for 45
seconds, 72°C for 1 minute.  Cycling was followed by a 10 minute 72°C extension
step was followed by a 4°C hold until PCR fragments were analyzed by gel
electrophoresis.
DNA gel electrophoresis
PCR products were visualized on 1X Tris acetate EDTA (TAE) buffer, 0.4
mg/ml ethidium bromide, 2.5% agarose gels.  60 volts were applied for
approximately 30 minutes to allow for 3-4 cm migration of the loading dye front.
PCR amplicons were visualized using an ultra violet light.
cDNA Synthesis and Indirect Fluorescent Dye Labeling for Commercial
microarrays
To generate fluorescently labeled cDNA probes for Clontech vendor array
hybridization, the recommended Atlas Glass Total RNA labeling kit (Cat # K1037-
1) was used.  This kit provided all reagents described below unless otherwise
specified.  Manufacturer’s recommendations of 20 mg of total RNA from each of
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the cell conditions described above was used in generating each labeling
reaction.  The 20 mg of total RNA was adjusted to 19 ml with deionized water, 5 ml
of Random Primer Mix supplied with the array and 1 ml cDNA synthesis control
(provided with the kit) was then added to the RNA sample.  The mixture was
heated at 70°C for 5 minutes and then cooled to 37°C.  25 ml of Master mix
containing 10 ml 5X cDNA Synthesis Buffer, 5 ml 10X dNTP Mix, 7.5 ml Deionized
H2O and 2.5 ml MMLV Reverse Transcriptase (200 units/ml) was then added, the
sample mixed and the reaction incubated at 37°C for 1 hour.  To generate cDNA
complex, the reaction was heated to 70°C for 5 min to activate the polymerase,
followed by a further incubation at 37°C for one hour.  0.5 ml RNase H (10
units/ml) was added and the 37°C incubation was continued for an additional 15
minutes.  To purify the cDNA, 0.5 ml of 0.5 M EDTA (pH 8.0) and 5 ml Quick Clean
resin was added to the mixture and was pipetted onto a 0.45- mm Spin Filter and
centrifuged at maximum speed in a microcentrifuge for 1 min.  The filter was
removed and discarded and 5.5 ml of 3M Sodium Acetate was added to the
supernatant.  137.5 ml of ice-cold 100% ethanol was added to the sample and
vortexed.  The cDNA was precipitated by a 1 hour incubation at –20°C and then
centrifuged at maximum speed in a microcentrifuge for 20 minutes.  The
supernatant was discarded and the pellet was washed once in 70% ethanol.  10
ml of 2X Fluorescent Labeling Buffer was added to the cDNA pellet for Indirect
Fluorescent Dye Coupling.  0.5 ml Coupling Reaction Control Oligo was added to
the cDNA sample and 10 ml of 5 mM fluorescent dye (cy3) and the mixture
incubated at room temperature for 30 minutes.  Fluorescent dye was kept in the
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dark at all times.  Fluorescent dye labeled cDNA was precipitated by the addition
of 2 ml 3 M sodium acetate and 50 ml 100% ethanol and placed at –20°C for 2
hours.  The tube was centrifuged at maximum speed in a microcentrifuge for 20
minutes.  The supernatant was carefully removed and the pellet washed once in
70% ethanol and air-dried.  The pellet was resuspended in 100 ml deionized H2O.
Purification of Fluorescent Dye Labeled cDNA
Fluorescent labeled cDNA was purified by a NucleoSpin ® Column Probe
Purification kit (Clontech Cat# K1037-1).  All buffers used in the probe purification
were provided with the Clontech kit unless otherwise specified.  400 ml of Buffer
NT2 was added to the 100 ml of cDNA sample applied to the NucleoSpin
Extraction Spin Column.  The flow-through was discarded and the column was
washed 3 times with 700 ml of NT3 buffer.  The column was centrifuged at
maximum speed for 1 min between each wash.  Purified and labeled cDNA was
eluted by the addition of 50 ml of NE buffer and centrifuged at maximum speed for
1 minute and repeated again to ensure complete elution.  The cDNA quantity and
cy3 incorporation efficiency was determined by spectrophotometry absorbency (A)
at 260nm, 280nm, 450nm, 550nm and 650nm.  Nucleic acid purity was
determined by calculating the A260/A280 ratio.  The expected value was between
1.8 and 2.0.  Nucleic acid/Cy3 incorporation ratio was calculated the A260/(A550
– A650) ratio.  The expected value was between 8 and 20.  Only probes with the
expected absorbances and ratios were used for hybridization to the microarrays.
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Commercial Microarray Hybridization
Clontech human Atlas glass 3.8I (Cat#7903-1) and 3.8II (Cat#7910-1)
microarrays were used for gene expression analysis.  The optimal amount of Cy3
labeled cDNA (Vopt) to be added to the array hybridization solution was
determined by the recommended formula, Vopt(ml)= (10/A550).  Labeled cDNA
was added to 2.1 ml of glass hybridization solution preheated to 50°C.  All
solutions were provided with the kit unless otherwise specified.  The entire
solution was mixed and quickly added to the hybridization chamber containing the
glass microarray.  The hybridization was conducted in the dark for a minimum of
16 hours at 50°C.  Without allowing the array to dry, the slide was washed with the
provided Clontech GlassHyb wash solution, twice with 1:10 GlassHyb wash and
1X Saline-Sodium citrate buffer (SSC), and once with 0.1 X SSC buffer.  The
glass array slides were dried by centrifugation at 1,500 rcf for 5 minutes.  Arrays
were stored in clean, dry and dark containers until image scanning.
Microarray Imaging and Analysis
The ScanArrayLite microarray analysis system by Packard Biosciences
was used to scan for Cy3 fluorescence on the microarray.  Laser power settings
and photomultiplier tube settings were adjusted according to maximal signal
without saturation or excessive background levels.  BMP files were generated to
save pictures of the fluorescence image and TIF files were saved for signal
intensity quantification.  TIF files were imported into Imagene 5.0 (BioDiscovery
Inc.) and signal intensity for each spot, corresponding to every gene was
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tabulated.  In close proximity to each spot, a background signal was also
measured.  Microsoft Excel files containing gene identification information spot
signal intensity and local background signal intensity were imported into
GeneSpring 4.2.1 software (Silicon Genetics Inc.) for data normalization and
analysis.  Arrays were normalized to total signal intensity across control and
sample slides.  Signal intensities less than 500 units were considered to be near
noise level and were statistically less reliable.  Genes were designated as highly
unreliable if both control and sample conditions generated signal intensity less
then 500 units.  Genes that had one or both conditions above 500 units remained
in the primary analysis list.  From this list, genes that showed a 1.5 differential in
control versus the FGF-23 sample were designated as potential genes of interest.
See tables 8 - 14 of the results section.
Custom Microarray design and construction
Target genes to be spotted were selected based on previous experimental
data, known association to bone mineralization and/or differentiation or phosphate
metabolism based on literature searches.  Bioinformatics analysis by Liu of
Genzyme Corp. identified human homologues to known yeast phosphate related
genes.  The oligos that were spotted onto the custom array were designed,
manufactured, and purchased from Operon.  Using Array Designer 2.0 (Premier
Biosoft International) hybridization oligos of 68 nucleotides in length, within 1,500
nucleotides of the known carboxyl terminus of the gene sequence and unique to
the human genome were designed.  The sequences were provided to Operon to
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construct the oligos.  All of the oligos were approximately 68-mers in length and
designed to be the sense strand.  The oligos were resuspended and adjusted to a
working stock of 500 mM based on measured optical density.  The oligos were
printed in quadruplicate onto 40 3D-Link slides (Motorola).  Quality control
validation of correct spotting and negligible carryover was conducted by
hybridization with Cy3-labeled random 9-mers to assess general slide quality.
The microarrays were stored in a vacuum chamber until used in the experiments.
cDNA Synthesis and Direct Fluorescent Dye Labeling for Custom arrays
Total RNA was isolated as described above.  A SpeedVac was used to
reduce the 20 mg RNA to a volume of 4 ml (5 mg/ml).  The volume was verified
manually by a pipetman and adjusted accordingly.  Total RNA was labeled using
FluorScript cDNA labeling kit (Invitrogen Cat# L1013-01).  The oligo(dT)12-18
primed direct labeling protocol was followed according to the manufacturer.
Labeled cDNA was purified with provided purification kit and materials.  500 ml of
loading buffer was added to the Cy3 labeled cDNA mix and added to the
purification column.  The column was centrifuged at 13,000 rcf and the
supernatant removed.  The column was washed twice with wash buffer and
centrifuged as previously described.  The purified and labeled cDNA was eluted in
100 ml of the provided elution buffer.  Hybridization, washing, imaging, and
analysis was conducted as previously described for the commercial microarray.
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Real-time PCR (SYBR Green)
RNA used for array hybridization was also used for real time RT-PCR
analysis of selected mRNAs.  Nine genes were selected for real time RT-PCR
validation based on preliminary array data and literature searches.  Table 4
contains the sequences of the forward and reverse primers.  PCR primers were
designed for 25-hydroxyvitamin D 1aOHase Accession number (Acc#) (Acc#
NM_000785), Vitamin D receptor-1 (Acc# NM_000376), 24OHase (Acc#
NM_000782), Parathyroid hormone receptor-1 (Acc# NM_000316), Parathyroid
hormone receptor-2 (Acc# NM_005048), Somatostatin receptor-2 (Acc#
NM_001050), Somatostatin receptor-3 (Acc# NM_001051), Somatostatin
receptor-4 (Acc# NM_001052), Calcitonin (Acc# NM_001741), Mucin-2 (Acc#
NM_002457), APC (Acc# NM_000038), AQP5 (Acc# NM_001651), AQP6 (Acc#
NM_001652) CTNNb (Acc# NM_001904) and GAPDH (Acc# AK026525) using
the Primer Express software program (PE Applied Biosystems).
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Table 4.  Primers designed for real-time RT-PCR validation.
Gene
name
size Forward primer 5’-3’ Reverse primer 5’-3’
25-hydro
D-1 alpha
72b GCTGGATGGCCTGAGGAAA GCCAGCAGCATCAATGAACA
DVR-1 70b CTGGCTGGCTAACTGGAAGC TGCCACACATTCCTGCCTT
24-hydro 78b CAGCACCATCTTCAGGTGCTT CAGCCTCCCTTTCATGTCATG
PTHr-1 74b GGCACTGGACTTCAAGCGAA TTGTGTGGGACACCATGGG
PTHr-2 73b GGAATCTCTCCGTGGACTGG ACGGTGGTGAGCACTGAGC
SSTr-2 74b AAGGTGAGCG GCACAGATG TCCGTGGTCTCATTCAGCC
SSTr-3 64b TCCCTCATGTGCCGCCT GGCAGAATATGCTGGTGAACTG
SSTr-4 67b CTGCGCCAACCCTATTCTCT GAGAACCCGCTGGAAGGATC
Calcitonin 70b CTCAGTGAGGACGAAGCGC CACTGGCCTTCATCTGCACAT
Mucin-2 61 CCCAACTTTGATGCCAGCA AGCATCCATTGGGCATGAA
APC 82 TGGAGCTCAGTAAAAGTAAAT
TCATGTAA
TGTGGGCCTATTATGCTCAATG
AQP5 60 CCCTGCGGTGGTCATGA ATGGGCCCTACCCAGAAAAC
AQP6 71 GGTGGGATAGAGGAAGGGAG
G
GGCAAGCACCTGGGAGG
CTNN
beta
73 TGAACTTGCATTGTGATTGGC GCACTTTCTGAGATACCAGCCC
GAPDH 226 GAAGGTGAAGGTCGGAGT GAAATCCCATCACCATCTTC
QuantiTect SYBR Green RT-PCR kit (Qiagen, Cat# 204243) was used to
quantify gene expression levels.  Total RNA isolated from cell culture samples
was used for real-time RT-PCR analysis.  Each 50 ml reaction contained 50 ng of
total RNA and 25 ml of 2x QuantiTect SYBR Green RT-PCR Master Mix, 0.5 ml
QuantiTect RT Mix, a final concentration of 0.5 mM of forward and reverse
primers.  To generate standard curves, final concentrations of 12 ng, 1.2 ng, 12
pg, 120 fg, 12 fg, and 0 fg of corresponding template oligonucleotides were added
to 50 ml reactions.  The real-time cycling conditions was as follows: 30 minutes at
50°C for reverse transcription, 15 minutes at 95°C for initial activation, followed by
40 cycles of 15 seconds at 94°C, 30 seconds at 60°C, 30 seconds at 72°C in a
real-time RT-PCR System 7700 (Applied Biosystems).  GAPDH was used as the
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housekeeping gene for sample normalization.  The PCR amplification product was
visualized on a 3% agarose ethidium bromide gel to ensure proper amplification of
a single band.
Delta CT analysis and GAPDH normalization
Comparative gene expression levels were determined following
manufacturer’s recommendations.  The GAPDH gene was used as a reference
and negligible variation was observed across samples.  CT is the threshold cycle
value for a sample.  CT values are collected incremental at each cycle but
assigned values are extrapolated to best fit the designated threshold value limit
assigned for the data analysis and therefore the CT is often not unit digit.  The
formula DCFGF = CFGF (target) – CFGF (GAPDH average) and DCcontrol = Ccontrol
(target) – Ccontrol(GAPDH average) was used to adjust sample values to a
common reference gene.  Comparative fold expression levels were calculated
with 2 - DDCT where FGF-23 treated and control cells were normalized to the
GAPDH reference gene.
Where: DDCT = DCT FGF-23 treated - DCT control   
Quantitative expression levels were obtained by comparison to a standard curve
of known spiked target numbers.
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RESULTS
Cell Line Selection
The purpose of these experiments was to gain a better understand of how
FGF-23 affects phosphate regulation by monitoring gene expression levels in cells
believed to be involved in mineral regulation.  Three cell lines representing the
small intestine, kidney, and bone were selected to monitor FGF-23 induced
differential gene expression.  As illustrated previously (figure 8a), PTH directly
affects calcium/phosphate reabsorption in the kidney and release of calcium and
phosphate from the bone.  Through its activation of 1,25(OH)2D3, PTH indirectly
affects phosphate absorption in the small intestine.  Similarly, FGF-23 may act on
all three tissues.  FGF-23 has been shown through in vivo studies to alter
expression of 1aOHase mRNA, which encodes the rate limiting enzyme for the
production of 1,25(OH)2D3  (Shimada, 2002).  Other genes are expected to be
modulated by FGF-23 in the human epithelial proximal tubule kidney cell line (HK-
2) as these cells represent the known functional site of action.  Several lines of
data suggest that HK-2 cells respond to FGF-23.  First, FGF-23 induced tyrosine
phosphorylation of several proteins within minutes of addition (Stephen O’Brien,
Genzyme).  Secondly, all known FGF receptors are expressed in HK-2 cells
(figure 9b).  Third, FGF-23 inhibited phosphate transport  (Ann Bowe, Genzyme).
Thus, HK-2 cells appear to be an appropriate cell line to study kidney specific
FGF-23 regulation of gene expression.
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The most accurate in vitro model available for the human small intestine
was a differentiation induced colorectal adenocarcinoma (Caco-2) cell line.  Prior
to differentiation of the Caco-2 cells, they express a large intestine phenotype as
demonstrated by the lack the type II NaPi transporter.  Following Caco-2
differentiation, the small intestine tissue specific sodium-dependent phosphate
transporter variant B of the type II NaPi gene was expressed (Karim-Jimenez et
al. 2000).  Again, tyrosine phosphorylation studies and receptor profiling suggests
that FGF-23 was capable of acting on the Caco-2 cells.
The human SaOS-2 cell line represents an epithelial osteosarcoma
osteoblast-like cell that expresses NaPi-3.  In addition to the NaPi-3 transporters,
gibbon ape leukemia virus receptor 1 (Glvr-1), also known as solute carrier family
20 (phosphate transporter) member 1 (PiT-1), is another known transporter
involved in phosphate regulation.  Although Glvr-1 is expressed in multiple tissue
types, it is the primary phosphate transporter found in bone.  Osteoblast-like
SaOS-2 cells are used to evaluate the effect of FGF-23 on bone related
phosphate regulation.  Preliminary western blot and receptor profiling data
indicates the FGF-23 can have a biological effect on SaOS-2 cells.  It is uncertain
which proliferative or differentiated state is optimal for observing the most
accurate model for phosphate regulation within the bone.  Some of the same
genes are expected to be regulated across all cell types but variation was
expected to be observed because the physiological functions are different and the
primary NaPi cotransporter through which phosphate is transported differs across
the three cell types.
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RT-PCR analysis of cell lines for FGF receptor expression
As discussed in the background section, FGFR 2,3 and 4 have been
shown to interact with FGF-23 in vitro.  Expression of these receptors by the
selected cell lines will support the likelihood of FGF-23 having a biological effect.
Forward and reverse PCR primers designed for the C terminal region of FGFR1-4
were used to screen for receptor gene expression in HK-2, Caco-2 and SaOS-2
cells.  The PCR products produced were of the expected size based on primer
positioning (see methods and material section).  The expected sizes for FGFR
1,2,3,4, and GAPDH are 370 bp, 330 bp, 320 bp, 360 bp, and 226 bp,
respectively.  The total RNA used as a template was DNase treated to ensure no
genomic contamination.  PCR products were not generated in the absence of
reverse transcriptase (RT) indicating that the RNA was indeed free from genomic
contamination.  Figure 9 shows that all three cell lines express FGFR1-4.  In
addition, HK-2 cells also express the FGFR-like 1 (FGFRL-1) receptor.  Of
particular interest was the expression of receptors 2, 3, and 4 in lanes 4, 6, and 8,
respectively.  It is likely that FGF-23 signals through one or a combination of these
receptors and their expression supports the likelihood of FGF-23 having a
biological effect on cell types tested.  The expression of FGFRL-1 was not tested
in Caco-2 cells (figure 9c).  FGFRL-1 lacks the cytoplasmic signaling domain and
hence is likely not to be directly involved in signal transduction.  FGFRL-1 may
compete for FGFR-1 ligand binding.
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The data from the cell line FGFR RT-PCR profiling indicates that the
receptors believed to be required for FGF-23 signaling are expressed in each cell
line and the cells are therefore likely to be capable of responding to FGF-23.
To further validate the likelihood that FGF-23 is capable of inducing a
signaling event within each cell type, O’Brien of Genzyme Corp tested total
protein tyrosine phosphorylation in response to FGF-23 treatment.  Cell lines that
express FGFR-2 and/or FGFR-4 showed elevated levels of tyrosine
phosphorylation using an anti-phosphorylated tyrosine immunoblot strategy,
suggesting a classical receptor signaling event.  Additionally, a negative control
cell line, U937, was also analyzed and as expected did not show FGFR
expression via RT-PCR (Data not shown).  Consistently, U937 cells did not show
400 bp
300 bp
Figure 9c.
1,    2,     3,     4,      5,     6,      7,     8,     9,    10,    11
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Figure 9b.
  1,   2,    3,   4,    5,    6,   7,    8,   9,   10,  11,  12, 13
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300 bp
Figure 9a.
  1,   2,    3,   4,    5,    6,    7,   8,   9,  10,   11,  12,  13
FIGURE 9.  Reverse transcriptase (RT)-PCR of FGFR genes.
Fig. 9a. SaOS-2 cells, Fig.9b. HK-2 cells. Fig 9c.Caco-2.
Lanes: 1.100 bp ladder, 2.FGFR-1, 3.RT negative FGFR-1,
4.FGFR-2, 5.RT negative FGFR-2, 6.FGFR-3, 7.RT negative
FGFR-3, 8.FGFR-4, 9.RT negative FGFR-4, 10.FGFRL-1,
11.RT negative FGFRL-1, 12.GAPDH, 13. RT negative
FGFR-1. Fig.9c. Lanes 10 GAPDH, 11, TR negative GAPDH.
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elevated phosphorylation in response to FGF-23 (O’Brien, Genzyme Corp., data
not shown).
FGF-23 purification
To generate purified preparations of FGF-23, wild type human FGF-23 was
expressed in bacteria (see methods and material section).  The intracellularly
expressed FGF-23 was purified using a double talon bead purification technique
that yielded a highly pure FGF-23 protein.  Specific conditions are described in the
methods and material section.  The recombinant bacterially produced FGF-23
contains a carboxy His tag to aid in purification and an anti-V5 epitope for
antibody detection.
FGF-23 was eluted from the talon beads and separated into four
homogeneous aliquots.  Bovine solution albumin (BSA) was added to one aliquot
of FGF-23 for a final concentration of 0.1% to act as a carrier to promote stability
of FGF-23 and then dialyzed overnight into phosphate buffered solution (PBS).  A
second aliquot of FGF-23 was dialyzed into PBS over night and then BSA was
added to a portion of the material post dialysis for a final concentration of 0.1%.  A
aliquot was not supplemented with BSA.  Figure 10a illustrates the relative purity
of each condition by coomassie gel.  Lane two of figure 10a shows the purity of
FGF-23 following the elution from the talon beads.  Similar purity of FGF-23 is
seen in lanes three and four but with the presence of BSA.  Figure 10b is an anti-
V5 -immunoblot of the same fractions.  Anti-V5 immunoblot analysis
demonstrated that the anti-V5 tagged FGF-23 was purified with the talon bead
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protocol (figure 10b).  A minimal amount of additional protein was detected at a
higher molecular weight with the anti-V5 antibody.
FGF-23 concentration was determined by bicinchoninic acid (BCA) assay
for samples without the addition of BSA.  Pre and post dialyzed FGF-23 without
BSA yielded 114 mg/ml and 74 mg/ml respectively.  An anti-V5 antibody ELISA
assay performed by Matijevic (Genzyme Corp.) on all four FGF-23 samples
showed a similar 30% loss due to dialysis.  FGF-23 with 0.1% BSA added prior to
dialysis, with an estimated final concentration of 74 mg/ml was used in subsequent
experiments.
The biological activity of anti-V5 and histidine tagged FGF-23 was
demonstrated by an opossum kidney phosphate uptake assay (conducted by
Bowe, Genzyme Corp.) and by induced gene expression measured by array
analysis.  FGF-23 for which BSA was added prior to dialysis exhibited a 40%
FIGURE 10.  Purified FGF-23.
Fig10a. coomassie stained gel. Lane 1.MWM,
2.prediaysis FGF-23, 3.Dialyzed FGF-23 with
0.1%BSA added predialysis, 4 Dialyzed FGF-
23 with 0.1% BSA added post-dialysis, 5.Post-
dialysis FGF-23 without BSA. Fig10b. anti-V5
antibody western blot. Lanes are same as
described above.  Arrow indicates FGF-23
     2       3     4      5
6kDa
14kDa
28kDa
38kDa
49kDa
62kDa
98kDa
     1   2   3   4   5
BSA
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inhibition of phosphate uptake at 20 ng/ml.  Although it is not known whether the
three variations from the endogenous form have subtle effects on FGF-23 action,
the bacterially produced protein demonstrates potent biological activity in the OK
phosphate uptake assay.  Appendix A shows the biological activity of the purified
FGF-23 used in the subsequent microarray analysis.
Selection of time points/Total RNA isolation from cell culture cells
Two time points were selected to collect RNA samples from FGF-23
treated cells.  All FGF peptides signal through one or more of the four known
functional FGF receptors.  As expected based on known signaling pathways for
other growth factors, including other FGFs, it is likely that FGF-23 elicits a series
of phosphorylation events which lead to rapid regulation of gene transcription
within minutes (Greenberg, 1993).  The earliest genes to respond to a growth
factor are typically transcription factors (immediate early response genes) that
induce the subsequent cascade of additional changes in gene expression.  Genes
encoding functions relevant to specialized changes in the cell are typically
regulated after hours or even days of growth factor stimulation.  As we were most
interested in identifying genes that encode functions specific to FGF-23 within this
study, later time points were selected to avoid measurement of early response
genes.  The earliest time points selected for collecting RNA samples was 24
hours based on initial reports that 1,25(0H)2D3 was induced in animals that
received repeated injections of FGF-23 over a 24 hour period (Shimada et al.,
2001).
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FGF-23 is linked to clinical phosphate dysregulation (OOM, XLH, ADHR)
where patients are exposed to elevated levels of FGF-23 for a prolonged period.
A prolonged exposure was also measured at a 72 hour time point.  For the cells
treated for 24 hours, FGF-23 was added at time zero and cells harvested 24
hours later.  For the cells treated for 72 hours, FGF-23 was added at time zero, 24
hours and 48 hours.  The repeated dosing was performed in an effort to mimic
prolonged FGF-23 exposure while compensating for a limited half life of the
protein.  A more robust transcriptional response was observed at the 72 hour time
compared to the 24 hour time point.  A more detailed discussion on the FGF-23
regulated genes can be found below.
Total RNA isolation from cell culture cells
Each cell line was treated with 50 ng/ml FGF-23 for 24 hours or 72 hours.
Cells were trypsinized, collected, and stored at –80o C until processed for RNA
extraction.  The isolated total RNA was DNase treated and the integrity of the
RNA was verified using a denaturing RNA gel.  The intact 28S and 18S ribosomal
RNA bands at approximately 4.5 and 1.9 kb demonstrated that the RNA was not
obviously degraded.  RNA for HK-2 cells are shown (figure 11), RNA from other
cell lines appear similar.
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RNA contamination by protein and/or DNA was assessed by spectrophotometer
optical density ratio measurements at 260nm absorbancy/280nm absorbency
which was always greater than 2.0.
RNA labeling for array analysis
Two fluorescent labeling methods were used to detect gene expression
quantities using microarrays.  The Atlas fluorescent indirect labeling kit
recommended by Clontech was used to prepare RNA that was hybridized to the
Clontech Atlas arrays.  In addition to the manufacturer’s recommendation, the
atlas labeling technique was used because initially Cy3 and Cy5 incorporation
was to be used.  Cy3 and Cy5 dyes were to be used so that FGF-23 treated and
control labeled RNA could be analyzed in the same microarray, hence reducing
inter-microarray variability.  Due to a size variation between the two dyes, an
indirect labeling method produces a more even incorporation into the probe
FIGURE 11.  Ethidium bromide stained reducing RNA gel. Lane 1.RNA MWM, 2.RNA from HK-
2 cells treated with FGF-23, 3.  RNA from HK-2 control cells without FGF-23 treatment. 2 mg of
total RNA is contained in each sample lane. No RNA degradation is observed.
1.35 Kb
2.37 Kb
4.40 Kb
 Lane   1     2      3
18S
28S
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representing the gene transcript than a direct labeling method.  In the indirect
labeling method, following the first-strand cDNA synthesis, a second step was
required to couple the fluorescent dye to the amino-modified cDNA.  In the direct
labeling method, fluorescent labeled dNTPs are directly incorporated during cDNA
synthesis.  Due to extensive Cy5 detection problems, Cy3 was the only
fluorescent dye used for detection.  Since dye incorporation variation was no
longer an issue, a direct labeling method was used for all custom array analysis.
The Invitrogen direct labeling technique required far fewer manipulations of the
RNA and hence generated less variability between RNA labeling preparations.
Cell line conditions and microarray strategy
Using the same batch of purified FGF-23, cells were treated with 50 ng/ml
FGF-23 in cell culture media for 24 hours or 72 hours.  As described in the
methods and material section, cells treated for 24 hours were given fresh media
containing FGF-23 at time zero and cells were harvested 24 hours later.  The cells
treated for 72 hours were given fresh media containing FGF-23 at time zero, 24
hours and 48 hours.  Control cells were given fresh media without FGF-23 at the
same intervals.  All cells were handled in as uniform fashion as possible.  The
entire batch of cells was processed to obtain DNA free total RNA.  The same RNA
batch was used for each of the three array analyses and subsequent real-time
RT-PCR validation, but the fluorescent dye labeling was processed independently
for each array hybridization replicate.
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 Three independent array types (Clontech Vol. I, Clontech Vol. II, and a
Custom array) were used to monitor gene expression levels at the two time
points.  Table 5 summarizes the number of RNA labeling and microarray
hybridization replicates analyzed at each condition.  RNA for each cell line
collected (24 hour and 72 hour time point) was obtained from a single in vitro
experiment.
Table 5.  Summary of replicate labeling and analysis of cell line conditions using Clontech human
atlas microarray volume 1, volume 2 and custom microarray.
Cell Type Condition Clontech
Vol. I
Clontech
Vol. II
Custom Array
HK-2 24 hr +/- FGF-23 3 2 1
HK-2 72 hr +/- FGF-23 1 1 1
Caco-2 24 hr +/- FGF-23 2 2 1
Caco-2 72 hr +/- FGF-23 2 2 1
SaOS-2 –G4 24 hr +/- FGF-23 1 1 1
SaOS-2 –G4 72 hr +/- FGF-23 1 1 1
In an effort to analyze most genes of potential interest prior to further
scrutiny, a cumulative list was generated containing all genes that were expressed
greater than 1.5 fold (FGF-23 treated / control cells) in both commercial
microarray I, II, and custom microarray at both 24 hours and 72 hours.  Typically,
a two-fold difference in expression is considered to be biologically significant.
However, to compensate for the lack of experimental replicates, the inherent
variability of the array technology, and the reduced dynamic range of the array
technology, it was decided to lower the cut-off limit to 1.5 fold difference.  It was
hoped that this strategy would identify gene expression trends across cell types,
time points, and array types.  By incorporating all genes with a 1.5 or greater fold
difference, fewer genes of potential biological relevance will be missed.  The
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consequence of this strategy will also mean that genes will require further
validation by another quantification tool to confirm expression levels since the
number of false negatives will likely be high.  The 1.5 fold up and down regulated
lists contained approximately 3200 genes that were differentially expressed at
least once (data not shown).  To reduce these lists to a more manageable size
and to help identify truly differentially expressed genes, emphasis was given to
genes that were reproducibly regulated in replicate experiments within one cell
type or across more than one cell type.  This strategy allowed a preliminary
assessment of the ability of FGF-23 to regulate gene expression across the
various cell types.  Furthermore, we hoped to observe general trends in the types
of genes regulated by FGF-23 using this approach.
Microarray data filtering
The unit of relative signal intensity measured by the array imaging system
can range from 0 to 100,000.  These values are arbitrary because they are
dependent on the power setting of the laser photo multiplier tube and gain setting.
The imaging settings were adjusted for maximal signal without saturation (near
100,000 units).  Values close to 500 are considered to be too close to background
signal intensity and require special attention.  Genes that generate a signal
intensity of less than 500 units in both treated and control condition were
discarded because the values are highly unreliable.  About 15% of the genes on
the commercial array and about 30% on the custom array never generated a
signal greater than 500 units.  Constant signals, for all tested conditions, below
63
the level of detection can be explained by poor hybridization specificity, low gene
expression, no gene expression, or unknown alternative splicing.  Genes that had
either the treated or control (but not both) less than 500 units were retained but
the calculated fold induction was unreliable.  These genes may have an important
biological role but since one condition was below the level of accurate detection,
an accurate fold induction could not be extracted, only a notable difference
between FGF-23 treated and control cells can be identified.  Since triplicate
microarray analysis was not conducted for all cell types at all time points, a
reliable fold induction required the validation by real-time RT-PCR.
Microarray caveats
Microarrays are a powerful tool to measure gene expression profiles.
Although this tool allows one to monitor a significantly higher number of genes
compared to other methods of mRNA analysis, the capability of the technology is
pushed to the limit by demanding greater sensitivity and qualitative answers.  Not
only is there great variability within the technology itself but the analytical
methodologies are still under development and no standard currently exists.
There are several sources of variability in processing a microarray.  There is
inherent variability in the probes, the pins used to spot the probes, array
preparation and fluorescent dye labeling of the target, hybridization processes,
background noise, spot overshinning effect, and image processing (Spruill et al.
2002).  While microarrays provide valuable insight into transcriptional gene
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regulation, for the previously mentioned reasons, the expression levels of selected
genes of interest should be validated by an alternative method.  Alternatively,
general information from the expression of families of genes or genes associated
with similar functions or pathways may be surmised from microarray analysis, but
it is important to utilize the information obtained from non-validated microarray
analysis, for the purpose of generating rather than proving a hypothesis.
Array variability assessment
To determine the variability of microarray data and to gain an
understanding of the potential degree of false positives and false negative data
points, replicate microarray data sets obtained from one biological sample (RNA
isolated from non-treated cells) were compared.  Under highly reproducible
conditions, two data sets normalized to total signal intensity should yield
consistent results where all data points would fall onto the middle diagonal line
when plotted against each other on the X and Y axis (Figure 12).  Each spot on
the graph represents a unique gene which is quantified on the microarray by a
fluorescent intensity.  The fluorescent intensity positioned in the X-axis represents
one data set and the Y-axis represents a second data set.  Data points that fall
above and below the two outside lines indicate a false 2 fold induction.  Various
sources may cause this variability including the indirect labeling technique
recommended by Clontech.  Additionally, as the signal intensity decreases, the
variability and likelihood of false signaling increases as seen in the lower left-hand
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corner of the graph.  For all of these reasons, only genes identified to be
differentially expressed in at least two separate array experiments were selected.
Genes of biologically relevant functions were chosen for validation using real-time
RT-PCR.
Figure 12.  Commercial microarray variability.  A comparison of two untreated controls.
Red represents an increase and blue corresponds to a decrease in gene expression.
Similar to the above commercial microarray variability assessments, the
custom microarrays were also tested for inherent false signaling (Figure 13).  One
difference between the two array types is that only 200 different genes were
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spotted on the custom array compared to 3,700 present on each commercial
array.  Each gene was spotted four times on the custom array, for a total of 800
spots, compared to only once on the commercial array.  The data points were the
average of the four gene signal intensities.  A direct labeling technique was used
instead of the previously discussed Clontech indirect labeling method.  Although
some variability is still observed, few false data points were seen to change
greater than 1.5 fold and these were mostly observed in genes expressed at very
low levels (figure 13).
Figure 13.  Custom microarray variability.  A comparison of two untreated controls.  Red
represents an increase and blue corresponds to a decrease in gene expression.
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Selected genes modulated by FGF-23 as identified by microarray analysis
Table 6 is a brief list of genes generated by cross referencing genes
identified to be differentially expressed using microarray analysis that had known
functions that are potentially related to FGF-23 function.  Expression ratios
represent the relative expression level of a particular gene in FGF-23 treated
samples relative to untreated samples.  Genes with a ratio of 1.5 or greater
represent potential candidate FGF-23 induced mRNA.  In contrast, genes with
expression ratios of less than 0.66 would represent potential candidate FGF-23
repressed mRNAs.
 The observation that the two PTH receptors were activated in two cell
types is of potential interest as it suggests that FGF-23 may regulate PTH action.
The family of parathyroid hormones (PTH) and hence PTH receptors (PTHR)
have been associated with calcium and phosphate homeostasis.  PTH receptor 1
and 2 is induced 2.1 and 7.65 fold (respectively) after 24 hours of FGF-23
administration in HK-2 cells and 1.7 and 2.3 fold (respectively) after 72 hours of
FGF-23 administration in Caco cells (Table 6).  An upregulation in PTH receptor
number could partially explain why net changes in PTH and calcium are not
observed.  Long term, an increased number of receptors could lead to increased
PTH efficacy without any changes in the actual levels of PTH protein.  PTH in turn
could counter the FGF-23 controlled down regulation of 1aOHase resulting in a
net balance of circulating 1,25(OH)2D3.  Differences in the level of PTH receptors
in response to FGF-23 were not observed in the SaOS cells despite the known
role of PTH in bone metabolism.
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Another class of receptors of potential relevance is the somatostatin
receptors.  Somatostatin (SST) receptor–2 is a marker for osteosarcoma tumors
of which OOM is a subclass (Jan de Beur et al. 2002b).  All the members of the
SST receptor family appear to be upregulated in the HK-2 cells between 1.7 and
2.7 fold (Table 6).
 Differential expression of several aquaporin (AQP) transporters was
observed in two cell types.  Induction ratios for AQP-5 and AQP-6 mRNA were 2.2
and 1.6 in the 72 hour SaOS samples, and 2.1 and 2.9 in the 24 hour HK-2
samples.  Of relevance is the observation that although AQP-5 and AQP-6
appeared to be induced at 72 hours in SaOS cells the ratios suggested a
repression by FGF-23 at 24 hours.  In addition, both genes appeared to be
repressed in Caco cells at 72 hours based on the observed ratios of 0.60 and
0.36. These apparent differential responses across cell types may indicate that a
different cellular response occurs in Sao-2 cells compared to HK-2 and Caco-2
cells.  Alternatively, it may reflect the inherent variability of the microarray
technique and suggest that the apparent difference in the expression of these
genes in all or a subset of the three cell types represent false positives.  It is
uncertain whether the Saos-2 respond in a completely different manner or
whether the cells were not in the appropriate cell state to robustly respond to
FGF-23 treatment.  However, it is apparent that the Saos-2 are transcriptionally
less responsive than the other two cell lines studied because fewer genes appear
to be differentially regulated.  Recent reports indicate that heparin sulfates
modulate FGF receptor/ligand specificity (Guimond and Turnbull 1999).  Current
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studies suggest that the various forms of heparin may affect FGF-23 specificity
differently under specific conditions.  Three forms of genes encoding heparin
proteoglycans were down regulated in HK-2 and Caco-2 cells but are not
significantly modulated in Saos-2 cells (table 6).
The biological significance of mucin–2 is unclear but it was observed to be
up regulated between 1.5 fold to 3.2 fold in all but one condition tested.  The
consistency of apparent upregulation across three cell types increases the
likelihood that mucin gene or mRNA is indeed a target for regulation by FGF-23.
One of several functions with which mucin-2 is associated is abnormal cell growth.
This function is consistent with other growth related and anti-apoptosis genes
modulated by FGF-23 throughout the various cell types and time points.
Expression of FRP-4 mRNA is a potentially repressed gene based on the
observed ratio of 0.61 in Caco cells treated for 72 hours.  SAGE analysis
demonstrated that FRP-4 upregulation is associated with OOM tumors (Jan de
Beur et al.  2001).  Similar to FGF-23, FRP-4 has also been demonstrated to
regulate phosphate transport in vitro (Bowe et al.  2001) and in vivo (Berndt et al.
ASN 2002).  FRP-4 has been linked to apoptosis in cartilage (Shimada et al.2001)
and similar to other FRP family members may inhibit Wnt action (Schiavi and Moe
2002).  Each gene specifically mentioned in this section was chosen for further
validation using real time RT-PCR (see below).
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The categorization of the genes listed in tables 6-13 represent general
functions currently associated with the gene that were obtained from Clontech
Atlas gene lists (BD Biosciences Cat# PT2593-CD), GeneSpring software
(SiliconGenetics) and/or National Center for Biotechnology Information (revised
October 10, 2001).  The genes may posses additional functions that are not
represented by the assignment of the categorization and the basic gene functions.
The assigned functions have not been individually confirmed through direct
literature review.
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Table 6.  Selected genes of interest up and down regulated greater than 1.5 fold from all cell lines,
both time points and both array times but values may not be statistically significant due to limited
replication of experiment.
Gene name Accession SaOS
24hr
SaOS
72hr
HK-2
24hr
HK-2
72hr
Caco
24hr
Caco
72hr
Basic function
Wnt related genes Average fold expression versus control
adenomatosis
polyposis coli
NM_000038 0.49 0.66 Binds beta-catenin, involved in Wnt
signaling
beta catenin –1 NM_001904 12.15 1.45 cell adhesion, signal transduction in the
Wnt pathway
Frizzle Related
Protein-4
NM_003014 0.61 Phosphatonin, associated with
phosphate wasting, and Wnt signaling
May be involved in
receptor binding
heparan sulfate
(glucosamine) 3-O-
sulfotransferase 1
NM_005114 0.54 0.58 generating numerous distinct heparan
sulfate fine structures that may play  a
role in FGF-23 specificity
heparan sulfate
(glucosamine) 3-O-
sulfotransferase 3A1
NM_006042 0.62 0.58 generating numerous distinct heparan
sulfate fine structures that may play  a
role in FGF-23 specificity
heparan sulfate
proteoglycan 2
(perlecan)
M85289 0.61 0.62 0.56 generating a myriad of distinct heparan
sulfate fine structures that may play  a
role in FGF-23 specificity
Calcium and
phosphate related
24-OHase NM_000782 2.07 Involved in calcium homeostasis,
catalyzes vitamin D into the active
state.
cadherin 15, M-
cadherin (myotubule)
NM_004933 1.8 0.37 calcium binding, calcium-dependent
cell adhesion molecule
FGF 23 NM_020638 0.23 Phosphatonin, associated with
phosphate wasting, growth factor
PTH receptor 1 NM_000316 2.1 1.70 Involved in serum calcium level
modulation
PTH receptor 2 NM_005048 7.65 0.65 1.5 2.3 Involved in serum calcium level
modulation
somatostatin receptor
1
NM_001049 1.7 Expressed in tubules and glomeruli of
human kidney, known to modulate
tubular cell function and growth
somatostatin receptor
2
M81830 1.7 0.45 1.73 Receptor involved in calcium and
phosphate regulation. OOM tumor
marker
somatostatin receptor
3
NM_001051 2.7 0.63 Receptor involved in blood sugar
modulation and cell growth
somatostatin receptor
4
NM_001052 2.6 Reported to be express in the human
kidney
Membrane channels
and transporters
aquaporin 5 NM_001651 0.65 2.2 2.1 0.60 water channel, primarily expressed in
salivary glands
aquaporin 6, kidney
specific
NM_001652 0.63 1.6 2.88 0.36 Nitrate specific water channel
cross cell type
expression
mucin 2,
intestinal/tracheal
NM_002457 2.3 1.7 3.2 1.5 2.2 Associated with abnormal growth and
protection against infection
72
As illustrated in table 5, the HK-2 24 hour condition was the only sample
analyzed three times using a single type of microarray.  Table 7 is a selected
compilation of up and down regulated genes that were reproducible identified to
be differentially expressed in triplicate repeat experiment using a single sample.
When averaging multiple array data points with signal intensity values above the
noise level (500 units of signal) 38 genes were identified to be consistently
regulated up or down.   As shown in table 7, several genes, in the 24 hour HK-2
samples, are involved in transcription (i.e. T-box 10 and paired-like homeodomain
transcription factor 1), differentiation (Beclin 1, Myeloid differentiation response
gene), and general changes in cellular metabolism (cytochrome P450, tubulin
specific chaperone).  No apoptosis inducing genes are seen.   The consistent
regulation across triplicate analysis strengthens the likelihood that the genes
represented in Table 7 are indeed targets of FGF-23 action.  As described below,
real-time RT-PCR analysis was performed on two genes listed in table 7,
aquaporin 5 and somatostatin 2.  As expected, results confirmed aquaporin 5 and
somatostatin 2 mRNAs are induced in HK-2 cells after 24 hours of treatment with
FGF-23 (figure 20 and figure 30 respectively).
73
Table 7.  Triplicate commercial microarray analysis of HK-2 genes up and down regulated 24
hours.
Gene Name Accession Basic function
General cell change
Ave
fold
adenylate cyclase 8 (brain) NM_001115 2.5 Enzyme involved in energy production
cytochrome P450, subfamily I NM_000499 0.34 Protein involved in the metabolism and
synthesis of cholesterol, steroids and lipids
G protein-coupled receptor 8 NM_005286 2.6 has similarity to somatostatin receptors may
regulate transport channels
pancreatic polypeptide NM_002722 2.2 Regulator of pancreatic functions
proline-rich protein BstNI subfamily 4 NM_002723 2.5  Function unknown, may interact with
concavalin-A binding proteins
Ribosomal protein L13a X56932 2.0 component of large 60S ribosomal subunit
signal recognition particle 14kD NM_003134 2.6 Subunit of protein targeting complex
somatostatin receptor 3 NM_001051 2.7 G protein-coupled receptor, signals through an
inhibitory G-protein
synapsin I NM_006950 1.7 Associated with neuronal growth and signaling
Tubulin-specific chaperone d NM_005993 43.9 Involved in tubulin formation/cellular movement
ubiquitin-conjugating enzyme E2E 1 NM_003341 2.2 may catalyze cellular proteins before
degradation
Cell differentiation
Carcinoembryonic antigen-related cell adhesion
molecule 3
NM_001815 2.3 May function in cell adhesion
cholinergic receptor, nicotinic, gamma polypeptide NM_005199 2.1 clustering of acetylcholine receptors (AChRs) is
an early sign of postsynaptic differentiation
Beclin 1 NM_003766 2.0 Anti-apoptosis
ES1 (zebrafish) protein, human homologue of NM_004649 6.2 Similar to E. coli SCRP-27A believed to be
involved in differentiation
myeloid differentiation primary response gene (88) NM_002468 2.0 Involved in myeloid differentiation
paired-like homeodomain transcription factor 1 NM_002653 2.3 Transcription factor that controls cell
differentiation
pre-B-cell leukemia transcription factor 2 NM_002586 2.1 very strongly similar to murine Pbx2 known to be
involved in differentiation
zinc finger protein 151 (pHZ-67) NM_003443 2.3 Function unknown contains zinc-fingers
Cell division
growth differentiation factor 10 NM_004962 0.46 TGF-beta family of growth factors member
RAD9 (S. pombe) homolog NM_004584 2.0 may function as a cell cycle checkpoint protein
during DNA synthesis
T-box 10 NM_005995 2.3 Polymerase II promoter transcription factor
TGFB inducible early growth response 2 NM_003597 3.7 Activates gamma-globin gene promoters
transcription factor 21 NM_003206 1.9 Expressed in kidney glomerular epithelial cells
TTK protein kinase NM_003318 3.1 Essential for spindle assembly maintenance
wingless-type MMTV integration site family,  5A NM_003392 0.48 Member of the Wnt family of cell signaling
proteins, involve in oocyte growth
X-ray repair complementing defective repair in
Chinese hamster cells 4
NM_003401 5.9 DNA synthesis and recombination
nuclear receptor subfamily, member 1 NM_000475 0.62 Inhibitor of growth by negative regulator of
transcription
Membrane channels and transporters
amiloride-sensitive cation channel 1, neuronal
(degenerin)
NM_001094 4.2 sodium channel permeable to lithium and
potassium ions
aquaporin 5 NM_001651 2.2 water channel
calcium channel, voltage-dependent, beta 2 subunit NM_000724 2.1 voltage-dependent calcium channel
solute carrier family 1, member 6 NM_005071 2.0 High affinity aspartate/glutamate transporter
solute carrier family 10, member 2 NM_000452 3.8 sodium/bile acid cotransporter family
Metabolism enzymes
arylsulfatase A NM_000487 2.7 Lysosomal arylsulfatase A; hydrolyzes
cerebroside sulfate
Phosphofructokinase, muscle NM_000289 2.9 enzyme required for glycolysis
phospholipase A2, group IB (pancreas) NM_000928 6.9 hydrolyzes the phospholipid sn-2 ester bond,
involved in signal transduction
serum deprivation response NM_004657 0.63 substrate for protein kinase C  which is involved
in cell signaling and calcium binding
Unclassified function
small proline-rich protein 2B NM_006945 1.9 Small proline rich protein
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 To obtain triplicate identification of up regulated genes across the three cell
types, experimental results were cross referenced.  The total number of times
each cell line condition was analyzed was previously shown in Table 5.  Genes
identified to be above the noise level and significantly up regulated in the five HK-
2 24 hour microarrays analysis experiments were combined.  The four 24 hour
microarrays analysis experiments for the Caco-2 cells were also combined and
the two SaOS-2 microarray analysis experiments were combined.  This provided
a conservative strategy, again in attempt to retain true positives that might have
arisen through averaging replicate experiments.  The smallest number of genes
identified as differentially expressed are in Saos cells partly due to the limited
number of replicate microarray data sets.  As shown in Figure 14a, 38 genes
appeared to be commonly up regulated in all three cell types at 24 hours and
Figure 14b shows 13 genes were universally up regulated at 72 hours.
Figure 14.  Venn diagram of up regulated genes on both Clontech microarray 1 and 2 at 24 hours
and 72 hours.
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Figure 14a.  24 hour time point.
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Figure 14b.  72 hour time point.
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As shown in Figure 14b, 38 genes are up regulated at 24 hours in all three
cell types as identified by commercially array analysis.  Table 8 lists the 38 genes
and the average fold induction as compared to the appropriate control. The genes
observed to be up regulated across all three cell types at the 24 hour time can be
categorized into similar biological classification as in the HK-2 24 hour triplicate
analysis discussed previously.  Genes in table 8 are generally associated with
cellular growth and differentiation through transcription and cellular
communication.  None of the genes in table 8 are currently known to be
associated with phosphate regulation or FGF-23 function.  However, protein
kinase C-like appeared to be upregulated an average of 3.13 fold and mucin-2
appeared to be upregulated an average of 2.57 fold.  Protein kinase C like-1 may
be associated with FGF ligand/receptor phosphorylation signaling and mucin-2
appeared to be most prominently upregulated by FGF-23 in all but one condition
tested.  It is not surprising that genes specifically associated with phosphate
regulation may not be contained on this list because different mechanisms and
pathways are believed to be involved in the method of phosphate regulation in the
three tissue types represented by the three cell lines.
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Table 8.  Genes up regulated an average of 1.5 fold or greater in all 3 cell types at 24 hours by
commercial microarray analysis.
Gene Name Accession Ave. Basic function
General cell change
Cbp/p300-interacting transactivator NM_004143 2.25 may be a transcriptional activator
hepatocyte nuclear factor 3, alpha NM_004496 2.66 transcription activators of liver-specific genes
immunoglobulin mu binding protein 2 NM_002180 2.44 involved in pre-mRNA processing and activation of
transcription
integrin beta 4 binding protein NM_002212 2.24 Links beta 4 integrin to intermediate filament cytoskeleton
intercellular adhesion molecule 4,
Landsteiner-Wiener blood group
NM_001544 2.06 participate in cell adhesion as well as cell-surface
mediated signaling
intercellular adhesion molecule 5,
telencephalin
NM_003259 1.69 participate in cell adhesion as well as cell-surface
mediated signaling
ladinin 1 NM_005558 2.48 may be an anchoring filament
leukemia inhibitory factor receptor NM_002310 3.14 Involved in transmembrane signaling through receptor
activation
major histocompatibility complex,
class II, DR beta 5
NM_002125 2.30 complex binds peptides and presents them to CD4+ T
lymphocytes
methionine-tRNA synthetase NM_004990 2.15 functions in protein biosynthesis
mitogen-activated protein kinase 11 NM_002751 1.97 activated by stress and proinflammatory cytokines
mitogen-activated protein kinase 13 NM_002754 2.27 activated by stress and proinflammatory cytokines
mitogen-activated protein kinase 10 NM_002446 2.45 APT mediated catalytic activity
mucin 2 NM_002457 2.57 Associated with abnormal growth and protection against
infection
myeloid differentiation primary
response gene (88)
NM_002468 2.65 Involved in immune response signaling pathway
polymerase (RNA) II (DNA directed)
polypeptide G
NM_002696 2.31 RNA polymerase II subunit
protein kinase C-like 1 NM_002741 3.13 Involved in phosphorylation mediated cell signaling
protein phosphatase 1, regulatory
(inhibitor) subunit 8
NM_002713 2.33 Activator of RNA decay
RAB5C, member RAS oncogene
family
NM_004583 2.59 Protein trafficing peptide
receptor-interacting serine-threonine
kinase 2
NM_003821 2.33 Enhances CASP-8-mediated apoptosis
RNA (guanine-7-) methyltransferase NM_003799 2.07 Involved in RNA capping
ubiquitin-conjugating enzyme E2E 1 NM_003341 2.23 may catalyze ubiquitination of cellular proteins prior to
degradation
ubiquitin-conjugating enzyme E2I NM_003345 1.81 ubiquitinates cellular proteins and marks them for
degradation
v-ral simian leukemia viral oncogene
homolog B
NM_002881 4.45 May be involved in transmembrane signaling
Cell differentiation
homeo box B2 NM_002145 2.10 may regulate gene expression, morphogenesis, and
differentiation
homeo box B3 NM_002146 2.43 may regulate gene expression, morphogenesis, and
differentiation
myogenic factor 3 NM_002478 2.13 transcriptional activator involved in skeletal muscle
differentiation
transforming growth factor, beta 3 NM_003239 1.73 cytokine family member , may be required for normal
development
Cell division
kinesin family member C3 NM_005550 3.44 may function in intracellular transport and mitosis
lectin, galactoside-binding, soluble, 7
(galectin 7)
NM_002307 2.51 Cell adhesion associated with normal cell growth and
differentiation.
pancreatic polypeptide NM_002722 2.35 mature peptide inhibits pancreatic exocrine function
semaphorin 3B NM_004636 3.58 involved in neuronal growth
tumor necrosis factor superfamily,  14 NM_003807 2.36 Growth modulator
Membrane channels and
transporters
solute carrier family 10 member 2 NM_000452 2.92 important for reabsorption of bile acids from small intestine
iduronidase, alpha-L- NM_000203 2.64 catalyzes degradation of disaccharides heparan
Unclassified function
immunoglobulin superfamily
containing leucine-rich repeat
NM_005545 2.13 may play a role in cell adhesion
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As described above, Figure 14b illustrates the number of genes appeared
to be commonly up regulated across three cell types at 72 hours as identified by
commercial microarray analysis.  Table 9 lists the 13 genes that appeared to be
commonly up regulated under these 72 hour conditions and the average fold
expression compared to control conditions.  The genes listed below belong to
various classifications but maintain a common theme of cellular growth and
differentiation.  Again, mucin-2 is observed to be potentially up regulated an
average fold of 2.19 in the three cell types at 72 hours.  Additionally, B lymphoid
tyrosine kinase appeared to be seen up regulated 3.79 fold.  The expression and
function of B lymphoid tyrosine kinase is consistent with the activation of FGFRs
by FGF-23 which results in a tyrosine phosphorylation cascade.  The function of
the genes in table 9 are not known to be directly linked to calcium and or
phosphate regulation but expression of paired gene box 4 and mucin-2 are known
to be involved in cancer growth.
Table 9. Genes up regulated an average of 1.5 fold or greater in all 3 cell types at 72 hours by
commercial array analysis.
Gene name Accession Ave. Basic function
General cell change
B lymphoid tyrosine kinase NM_001715 3.79 involved in tyrosine phosphorylation
mucin 2 NM_002457 2.19 Associated with abnormal growth
and protection against infection
Cell differentiation
ATPase, H+/K+ exchanging, beta polypeptide NM_000705 2.23 Involved in transport
sialyltransferase 6 NM_006279 1.84 metabolism enzymes
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 5
NM_004776 3.03 metabolism enzymes
Cell division
glutathione S-transferase theta 2 NM_000854 2.20 anti-apoptosis
hyaluronoglucosaminidase 1 NM_007312 2.16 cell growth and differentiation
metargidin, domain 15 (metargidin) NM_003815 2.20 cell growth; cell-matrix adhesion
myeloid/lymphoid or mixed-lineage leukemia 2 NM_003482 1.68 transcription factor
paired box gene 4 NM_006193 1.60 transcription factor
RNA binding motif protein 3 NM_006743 1.78 Involved in RNA binding
Unknown function
chromosome X open reading frame 5 NM_003611 2.09 Protein coding region
DNA segment on chromosome 21 (unique) 2056 expressed
sequence
NM_003683 2.28 Protein coding region
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To obtain triplicate identification of down regulated genes across the three
cell types, experimental results were cross referenced in a similar manner as
described previously for up regulated genes.  The total number of times each cell
line condition was analyzed is described in Table 5.  Genes identified to be above
the noise level and significantly down regulated in the five HK-2 24 hour
microarray analysis experiments were combined.  The four 24 hour microarrays
analysis experiments for the Caco-2 cells were also combined and the two SaOS-
2 microarray analysis experiments were combined.  As shown in Figure 15, 15
genes appeared to be commonly up regulated in all three cell types at 24 hours,
and 15 genes appeared to be down regulated at 72 hours.
Figure 15.  Venn diagram of down regulated genes on both Clontech microarrays 1 and 2 at 24
hours and 72 hours.
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Figure 15a.  24 hour time point.
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Figure 15b.  72 hour time point.
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Table 10 lists the gene names and the average fold down regulation at 24
hours as shown in figure 15a.  Genes associated with inhibition of transcription,
apoptosis, and differentiation are potentially down regulated at 24 hours.  The
expression level of D-aspartate oxidase appeared to be down regulated 6.25 fold,
the greatest at 24 hours.  This gene was also identified as down potentially
regulated in OOM tumors compared to non-OOM mesenchymal tumors in SAGE
analysis conducted by Genzyme Corp.  This parallel observation observed
between two technologies and four biological samples, one of which represents a
relevant in vivo condition, supports the likelihood that this gene is indeed an
important target for FGF-23 regulation.  Furthermore, the observation that this
gene appears to be repressed in vitro by FGF-23 and in vivo in tissues over-
expressing FGF-23 relative to histologicaly similar samples not expressing FGF-
23, supports the hypothesis that some of the OOM associated genes are
regulated directly by autocrine actions of FGF-23 in these tumors.
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Table 10.  Down regulated genes an average 1.5 fold or greater in all 3 cell types at 24 hour
A value of 0.666 or smaller indicates a significant down regulation of 1.5 fold or greater.
Gene name accession # Fold
down
Fold
up
Basic function
General cell change regulated
D-aspartate oxidase NM_004032 6.25 0.16 Aspartic acid catabolism, repressed
in OOM
dysferlin, limb girdle muscular dystrophy 2B
(autosomal recessive)
NM_003494 2.04 0.49 involved in membrane regeneration
and repair
eukaryotic translation initiation factor 3,
subunit 5 (epsilon, 47kD)
NM_003754 3.85 0.26 stabilizes translation initiator
subunits
Fas (TNFRSF6)-associated via death
domain
NM_003824 3.23 0.31 Required for apoptosis signaling
interleukin 18 receptor 1 NM_003855 2.44 0.41 immune response, signal
transduction
JAK binding protein NM_003745 2.86 0.35 suppressor of cytokine signaling
KH-type splicing regulatory protein (FUSE
binding protein 2)
NM_003685 2.44 0.41 Specific mRNA splicing of integrin
signaling to the cytoskeleton.
mitogen-activated protein kinase-activated
protein kinase 3
NM_004635 4.00 0.25 integrative element of signaling in
both mitogen and stress responses
olfactory receptor, family 3, subfamily A,
member 1
NM_002550 2.56 0.39 olfaction, signal transduction
small inducible cytokine subfamily A,
member 13
NM_005408 3.13 0.32 immune response
syntaxin binding protein 2 NM_006949 2.22 0.45 intracellular protein traffic, and binds
neurotransmitters that are released
during calcium-regulated exocytosis
Membrane channels and
transporters
sodium channel, voltage-gated, type I, beta
polypeptide
NM_001037 1.75 0.57 ion and sodium transport
Cell division
histone acetyltransferase 1 NM_003642 3.85 0.26 DNA packaging, S-phase of DNA
replication
numb homolog NM_003744 4.17 0.24 generating asymmetric cell division
during neurogenesis
Unknown function
Ric NM_002930 2.50 0.40 Calmodulin binding protein, function
unknown
Table 11 contains the genes that are potentially down regulated at 72
hours as shown in figure 19b and the average fold expression compared to the
control condition.  Transcription and translation related genes appear to be down
regulated at 72 hours.  Interferon alpha 13 was seen to be potentially down
regulated the greatest at a 2.86 average fold compared to the control condition.
Tumor suppressor oncogene homolog B, which is associated with tumor
suppression and calmodulin binding, appeared to be down regulated 2.27 fold.
Calmodulin is involved in regulation of serum calcium levels and provides an
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additional association of FGF-23 to calcium homeostasis similar to PTH related
genes.
Table 11.  Genes down regulated 1.5 fold or greater in all 3 cell types at 72 hour
A value of 0.666 or smaller indicates a 1.5 fold or greater down regulation.
Gene name Accession # Fold
down
Fold
up
Basic function
General cell change regulated
actin, gamma 1 NM_001614 2.27 0.44 mediators of internal cell motility
interferon, alpha 13 NM_006900 2.86 0.35 defense response
mesenchyme homeo box 2 NM_005924 1.96 0.51 transcription regulation
phosphodiesterase 6D, NM_002601 2.27 0.44 solubilizes the normally
membrane-bound holoenzyme
protein phosphatase 1, regulatory subunit 8 NM_002713 2.22 0.45 mRNA splicing, RNA catabolism
protein tyrosine kinase 9 NM_002822 2.27 0.44 protein amino acid
phosphorylation
pyrimidinergic receptor P2Y NM_004154 2.00 0.50 mediates cellular signaling
responses to nucleotides
retinoic acid receptor, alpha NM_000964 2.38 0.42 stimulates transcription in a
ligand-dependent manner
ribosomal protein L3 NM_000967 1.72 0.58 protein biosynthesis
ribosomal protein S16 NM_001020 2.70 0.37 protein biosynthesis
small nuclear ribonucleoprotein polypeptide F NM_003095 1.69 0.59 mRNA splicing
v-ral simian leukemia viral oncogene homolog B NM_002881 2.27 0.44 oncogenes and tumor
suppressors, differential binding
of calmodulin
Cell division
POU domain, class 2, associating factor 1 NM_006235 2.63 0.38 Involved in translational
regulation of growth inhibitor in
response to stress
procollagen C-endopeptidase enhancer NM_002593 2.13 0.47 cell growth and/or maintenance
Custom microarray analysis of FGF-23 induced genes
As described above, approximately 200 genes were selected which encode
biological functions in pathways postulated to be regulated by FGF-23 and
analyzed by custom array.  Every gene was spotted four times on each custom
microarray.  The average signal intensity for the four spots was calculated for
RNA obtained from cells treated with FGF-23 and the fold induction was
determined by comparison to signal intensity generated by RNA obtained from
untreated cells.  A 1.5 fold difference was used as a criterion for identifying
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potentially significant gene regulation differences.  Table 12 contains the names
and fold expression of genes observed to be increased in expression by custom
microarray analysis and table 13 contains genes observed to be decreased in
expression.
Table 12.  Genes up regulated greater than 1.5 fold on custom arrays.
Gene name accession SaOS
24hr
SaOS
72hr
HK-2
24hr
HK-2
72hr
Caco
24hr
Caco
72hr
Basic function
Apoptosis
Protein kinase C inhibitor
protein-1
(14-3-3)
NM_003406 3.57 Interacts with kinase mediate
signal transduction
Bone mineralization
related
Bone morphogenetic protein 4
(BMP4)
NM_001202 1.68 ossification
Glvr2 (Pit-2) NM_006749 1.46 phosphate transport
Osteocalcin NM_000711 1.56 1.47 Binds strongly to calcium,
ossification
PTH receptor 1 NM_000316 1.70 Involved in serum calcium level
modulation
House keeping
alpha Tubulin NM_006082 15.26 1.46 microtubule-based movement
Cyclophilin -A NM_021130 11.06 Involved in immunosupressant
activity
GAPDH NM_002046 5.15 Second phase of glycolysis
Human homologues to
Yeast Phosphate genes
CATD_HUMAN Cathepsin D
precursor
NM_001909 4.00 Required for intracellular protein
breakdown
IMB3_HUMAN Importin beta-3
subunit (Karyopherin beta-3
subunit)
Y08890 1.85 plays a role in nuclear import of
some ribosomal proteins
Sodium-dependent high-affinity
dicarboxylate transporter
NM_022829 1.50 sodium-dependent
dicarboxylate transporter
OOM related
Alpha-actinin mRNA NM_004924 6.74 Intravellular structural/bundle
protein
Apolipoprotein J mRNA NM_001831 1.41 1.59 Function uncertain but may
have  anti-apoptosis role
BTF 3b mRNA NM_001207 1.62 transcription regulation,
transcription, from Pol II
promoter
CD74 antigen NM_004355 3.11 Involved in immune response
initiation and antigen
presentation
diacylglycerol kinase, zeta NM_003646 8.95 1.47 1.81 intracellular signaling cascade,
protein kinase C activation
EST (hypothetical protein
MGC2491)
NM_024040 2.141 Protein coding sequence
EST (Kruppel-like factor 13) AL390127 1.59 1.90 Transcription repressor
EST(hypothetical protein
MGC4022)
NM_033420 2.87 Protein coding sequence
Fibronectin-1 NM_002026 10.33 cell adhesion and migration
processes
HSMN P1 NM_018478 1.7 Chromosome 20 open reading
frame
IGF-2 (insulin-like growth factor NM_000597 1.43 regulation of cell growth
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binding protein 2)
Jumping Translocation
breakpoint
NM_006694 2.19 Linked to oncogenesis
Lamin C mRNA NM_005572 2.28 Thought to provide for nuclear
envelope structure, cell shape
and cell size control
Leukemia Virus Receptor
(Glvr-1)
NM_005415 1.48 Sodium dependant phosphate
transporter
oligomeric matrix protein NM_000095 2.87 1.48 cell adhesion, cartilage matrix
and skeletal development
Prepro Alpha-1 Collagen mRNA NM_000088 1.66 Bone mineralization and
skeletal development
RTP mRNA NM_006096 1.50 Associated with cell
differentiation, may have growth
inhibitory role
TGF beta NM_000660 1.70 anti-apoptosis, cell growth, cell-
cell signaling, developmental
processes, TGF beta receptor
signaling pathway
Osteoblast Markers
JunD NM_005354 9.70 play a critical role in terminating
cell proliferation in granulocytic
differentiation
Wnt Related
beta catenin -1 NM_001904 12.15 1.45 cell adhesion, signal
transduction in the Wnt pathway
sFRP-5 NM_003015 1.39 1.87 2.25 May modulate Wnt protein
function associated with
oncogenesis and several
developmental processes
GAPDH was observed to be upregulated 5 fold in HK-2 cells (table 12) but
when measured with real-time RT-PCR (data not shown) no change in expression
was observed, suggesting a false positive.  Similarly, FRP-4 was observed to be
downregulated 1.6 fold (table 13) but no significant change was observed when
test by real-time RT-PCR (figure 19) suggesting a false negative.  Detection of
false positives and false negatives by custom microarray analysis is not surprising
because the samples were only tested once due to limited mRNA availability and
a lack of robust signal.  For these reasons, the apparent differential expression of
house keeping genes alpha Tubulin (table 12and 13) and Cyclophilin -A (table 12)
are not of notable concern but should not be simply dismissed.  Five genes with
novel association to phosphate, as identified by bioinformatics homology analysis
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to known yeast phosphate genes were also identified to be differential expressed.
Additional validation of these genes is required to determine validity of fold
expression.  A greater than 1.5 fold differential expression of sodium-dependent
high-affinity dicarboxylate transporter (table 12) and PIX1 pituitary homeobox 1
(table 13) was measured.  The level of expression, as measured by unit
fluorescence, for FGF-23 treated and control cells was robust and therefore more
likely to represent an accurate fold change in expression.  The sodium transporter
and PIX1 should be the first of the yeast phosphate genes to be validated by real-
time RT-PCR.
Table 13.  Genes decreased in expression greater than 1.5 fold on custom microarrays.
Gene name Accession SaOS
24hr
SaOS
72hr
HK-2
24hr
HK-2
72hr
Caco
24hr
Caco
72hr
Basic function
Bone related
Bone morphogenetic protein 2
(BMP2)
NM_001200 0.67 cell-cell signaling, ossification
gremlin NM_013372 0.66 Blocks bone morphogenic
protein signaling
Paired box gene 3 (PAX-3) BC008826 0.54 genes play critical roles during
fetal development and cancer
growth
vitamin D (1,25-
dihydroxyvitamin D3) receptor
NM_000376 0.59 signal transduction, involved in
maintenance of calcium
homeostasis
House keeping
alpha Tubulin (ubiquitous) NM_006082 0.6 microtubule-based movement
Human homologues to
Yeast Phosphate genes
PIX1_HUMAN Pituitary
homeobox 1 (Hindlimb
expressed homeobox protein
NM_002653 0.37 may regulate gene expression
and control cell differentiation
Sodium-dependent high-affinity
dicarboxylate transporter
NM_022829 0.38 sodium transport
OOM related
23810 Osteopontin NM_000582 0.55 cell adhesion, ossification
ANK NM_054027 0.32 Involved in phosphate level
modulation, possible mechanism
regulating tissue calcification
Calmodulin NM_006888 0.64 Calcium binding protein involved
in growth and cell cycle
CD44 Splice variant w/in coding
(zinc finger protein 6 (CMPX1))
AJ251595 0.29 may play an important role in the
pathogenesis of human tumors
Chondroitin-6-sulfotransferase AB017915 0.65 0.5 Extracellular matrix maintenance
CSR-1 NM_016240 0.15 Protects against stress response
double Leman coiled-coil
protein (was NME)
NM_016201 0.51 Unknown function
EST (FKSG14) AF5alpha NM_022145 0.53 leucine zipper binding protein
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EST (Kruppel-like factor 13) AL390127 0.36 Transcription repressor
EST(hypothetical protein
MGC4022)
NM_033420 0.64 Protein coding sequence
EST/distal-less homeobox
protein (DLX3)
AF028233 0.65 developmental processes,
skeletal development
FGF 23 NM_020638 0.23 Phosphatonin, associated with
phosphate wasting
FGF acidic NM_004214 0.49 cell-cell signaling, induces
various morphogenic changes
and differentiation
Frizzle Related Protein-4 NM_003014 0.62 Phosphatonin, associated with
phosphate wasting, signal
transduction
hSHIP NM_005541 0.17 May be involved in inhibition of
apoptosis
Human O-linked GlcNAc
transferase
NM_003605 0.01 Involved in O-linked glycosylation
HVEB mRNA NM_002856 0.64 mediates entry of some
alphaherpesvirus mutants,
involved in cell to cell spreading
of the virus
Hypothetical protein FLJ10199 NM_018022 0.64 Protein coding sequence
integrin alpha 10 AF112345 0.19 Involved in cell adhesion as well
as cell-surface mediated
signaling
Jumping Translocation
breakpoint
NM_006694 0.67 Linked to oncogenesis
Lamin C mRNA NM_005572 0.6 Thought to provide for nuclear
envelope structure, cell shape
and cell size control
leucine rich repeat (in FLII)
interacting protein 2
(canidate20)
NM_006309 0.41 canidate20
MEF-2A NM_005587 0.33 May be involved in growth factor-
related transcription
Milk Fat Globule-EGF 8 Protein NM_005928 0.56 cell adhesion, oncogenesis
MRG-1 protein AF109161 0.3 transcription regulation
Neurogranin RC3 mRNA NM_006176 0.49 0.59 Binds to calmodulin in the
absence of calcium
Novel gene hom. to sulfatase
Novel (Candidate 46) or
KIAA1077 protein
AB029000 0.39 Protein coding sequence
Plectin (PLEC-1 mRNA) NM_000445 0.42 0.54 cytoskeletal anchoring
Prostaglandin I2 Synthase NM_000961 0.58 inhibitor of platelet aggregation
Selenoprotein P NM_005410 0.16 Heparin binding protein
Serine Protease 11 (IGF
Binding)
NM_002775 0.59 regulation of cell growth
THC 3' 286255 ninjurin 2) BC015737 0.38 neuronal cell adhesion
TIAM-1 variant NM_003253 0.23 Involved in  intracellular signaling
cascade
transcription factor 7-like 2 NM_030756 0.49 transcription regulation
Osteoblast Markers
alkaline phosphatase NM_000478 0.5 post-translational membrane
targeting,  linked directly to
hypophosphatasia, a disorder
that is characterized by
hypercalcemia and includes
skeletal defects
CSF-1 M37435 0.58 0.48 antimicrobial humoral response,
positive control of cell
proliferation
double Rank ligand (OPG, TR1,
OCIF) product osteoprotegrin
NM_002546 0.56 This protein is an osteoblast-
secreted decoy receptor that
functions as a negative regulator
of bone reabsorption
Wnt Related
APC NM_000038 0.54 0.66 cell adhesion, binds beta-actin
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Real-time RT-PCR technology used to validate leads generated by arrays
TaqmanTM is a real-time polymerase chain reaction (PCR) quantification
technology patented by Perkin-Elmer.  As microarrays are useful for screening a
large variety of genes for expression patterns, real-time RT-PCR is lower
throughput but allows for accurate validation of selected gene expression.
Traditional sequence specific forward and reverse primers were used to amplify
the target sequence.  Through temperature cycling, double stranded product is
generated.  Real-time detection and quantification of the amplified fragment is
achieved by a SYBR green fluorescent dye.  Qiagen has developed a user-
friendly kit to be used on a real-time PCR technology.  Buffer conditions are
optimized so that the SYBR green dye efficiently binds to double stranded DNA
generated by the amplification process.  SYBR green dye fluoresces only upon
double stranded DNA incorporation.  The Qiagen QuantiTect SYBR Green RT-
PCR kit is used on the Perkin-Elmer real-time RT-PCR system to validate leads
identified by array analysis.  Several genes of interest identified from initial array
data and literature were selected for real-time RT-PCR validation.  Their published
functional properties associate each gene with either calcium or phosphate
related regulation.
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Calculation of standard deviation
Standard deviation was calculated for real-time RT-PCR analysis. The
formula used is:
Stdev = (nSx2 –(Sx)2)/(n(n-1))
Where n is the number of replicates and x is the value of the data point
signal intensity. Samples were analyzed in triplicate so n is equal to 3 for all real-
time RT-PCR analysis unless otherwise noted.
Real-time RT-PCR validation
Real-time RT-PCR validation was conducted on selected genes identified
from microarray analysis.  Standard curves were generated using known
concentrations of template oligos for all genes tested except aquaporin-5 to
ensure that the analysis was performed in the linear range of the assay (figures
21-26).  Furthermore, agarose gel electrophoresis analysis was performed to
confirm absence of contaminating bands.  Adenomatosis polyposis coli (APC)
was selected for validation by real-time RT-PCR because of the observed 1.5 fold
reduced expression by microarray analysis in two cell types and the association of
APC to the Wnt signaling pathway.  The Wnt pathway is of relevant interest
because the family members of FRP-4 (another phosphatonin) is know to interact
with WNT signaling and may create a synergistic effect on phosphate regulation
(Anderson et al. 2002).  Although a dramatic change in expression was not
observed in either microarray or real-time RT-PCR analysis, both methods
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showed a consistent 1.5 fold down regulation of APC.  A down regulation of APC
is associated with activation of the Wnt pathway and is consistent with the
potential upregulation of beta-catenin observed by microarray analysis of HK-2
and Caco-2 cells at 72 hours.  It is difficult to assess whether a 1.5 fold repression
is biologically relevant, but the consistency of the data would suggest that this
gene should be further assessed in other cell types or within experiments that
monitor a broader range of FGF-23 treatment times.
Figure 16. APC expression analysis of Caco-2 and HK-2 cells treated with FGF-23 for 24 hours by
microarray and real-time RT-PCR.
The parathyroid hormone (PTH) signals through the PTH receptor (PTHR)
1 and 2.  In response to low serum calcium levels, PTH is increased (Juppner et
al. 1999).  An increase in PTH reduces the reabsorption of phosphate in the
kidney hence resulting in phosphate wasting.  The association of PTHr-2 to
phosphate homeostasis prompted the desire for RT-PCR validation of the
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observed microarray upregulation in HK-2 cells at 24 hours.  However, it is
important to point out that although PTHr-2 appeared to be induced in the first
array analysis of this mRNA sample, a reproducible induction was not observed in
replicate array analysis.  Based on this result, it was not surprising to observe that
upregulation of PTHr-2 was not supported by the RT-PCR data (figure 17).
PTH also modulates calcium and phosphate homeostasis through
regulation of vitamin D levels.  An increase in PTH increases 1aOHase which is
the key metabolic enzyme that converts the inert vitamin D (25(OH)D3) into the
active state of 1,25-dihydroxyvitamin D (1,25(OH)2D3).  24-hydroxylase
(24OHase) degrades the active 1,25(OH)2D3 to an inert 1,24,25(OH) 2D3 form
allowing for tight regulation of vitamin D activity and hence calcium homeostasis
(Holick 1999).  FGF-23 has been shown to repress renal expression of 1aOHase
in vivo (Shimada et al. 2002).  Changes in expression of this gene were not
observed by array analysis because all signals fell below the background level of
500.  However, consistent with a predicted repression of the anabolic 1aOHase,
array analysis suggested FGF-23 may induce expression of the catabolic enzyme,
24-OHase as an expression ratio of 2.07 was observed in Caco-2 cells at 24
hours.  RT-PCR results showed that in the intestinal Caco-2 cells at 24 hours,
FGF-23 treatment increased 1aOHase 2 fold, while no change was observed in
24OHase (figure 17).  The RT-PCR result would suggest that production of
1,25(OH)2D3 would increase.  Direct measurement of 1,25(OH)2D3 would be
required to validate this conclusion.  These results (figure 17) are opposite from in
vivo studies (Yamazaki 2002, Shimada ASBMR 2002) by a decrease in renal
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1aOHase was observed at 1-9 hours after FGF-23 treatment, but expression level
at 24 hours was not analyzed in that study.  Patients with OOM tumors have a low
level of 1,25(OH)2D3 and return to normal upon removal of the tumors (Yamazaki
et al. 2002).  The Caco-2 24 hour in vitro results are inconsistent with the
Yamazaki in vivo data.  Perhaps a prolonged treatment of Caco-2 cells with FGF-
23 would result in a measured decrease in 1aOHase levels.  Alternatively,
measurement of 1aOHase levels at a more optimal time point (1-9 hours post-
FGF-23 treatment) would result in measured decrease.  Alternatively, these
results may support a differential role in the regulation of 1,25(OH) 2D3 in the
intestine compared to the kidney.  A third possibility is that the observed changes
at 24 hours may be a reflection of an FGF-23 induced feedback on the
maintenance of 1,25(OH) 2D3.  It is also interesting to note that specific changes
observed in the renal cell line, HK-2 despite the existing in vivo data.  These
results may reflect the inherent inability of the cells to maintain a true renal
epithelial cell phenotype under culture conditions.
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Figure 17.  Vitamin D related gene expression analysis of Caco-2 and HK-2 cells treated with
FGF-23 for 24 hours by microarray and real-time RT-PCR.
Mucin-2 was observed to be consistently expressed 1.5 fold greater in
FGF-23 treated cells than the control condition (figure 18).  Both 100 ng and
400ng of starting total RNA for the real-time RT-PCR template yielded similar fold
induction but with better reproducibility with more template.  Tables 6, 7, and 8
(shown previously) show the putative upregulation of mucin-2 in all the tested
conditions except for Caco-2 at 72 hours.  Real-time RT-PCR validation of the
HK-2 cells treated for 24 hours showed a change in expression and that was
slightly less than 2X and was less robust than indicated by microarray analysis
(figure 18).  Again, analysis of this gene across different FGF-23 exposure times
would be valuable to identify maximum induction of this gene by FGF-23
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Figure 18. Mucin-2 expression analysis of HK-2 cells treated with FGF-23 for 24 hours by
microarray and real-time RT-PCR.
FRP-4 was previously identified to be upregulated in OOM tumors by
SAGE analysis (Jan de Beur et al. 2002a), and since then has been demonstrated
to be a phosphatonin.  Microarray analysis suggested that FRP-4 might be
downregulated in Caco cells at 72 hours since the expression level was 0.6 (Table
6).  A modest reduction that did not approach the 1.5X cut-off was observed at 24
hours (ratio 0.75).   Due to the limited availability of the 72 hour sample, real-time
RT-PCR validation was conducted on Caco-2 RNA collected at 24 hours (figure
19).  Real-time RT-PCR analysis showed conflicting results of a 1.68 fold
expression compared to 0.6 by array (Figure 19).  These results did not support
regulation of FRP-4 by FGF-23 and suggested that the observed changes may be
due to inherent variability of the array technology or lack of biological replicates.
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Figure 19.  FRP-4 expression analysis of Caco-2 cells treated with FGF-23 for 24 hours by
microarray and real-time RT-PCR.
Aquaporins (Aqp) are a family of extracellular membrane bound water
channels expressed in various organs.  Aqp-5 and Aqp-6 were identified to be
upregulated in HK-2 cells after 24 hours of FGF-23 treatment (Table 6).  Although
Aqp-5 is structurally similar to the other family members, it is unique because it is
expressed intracellularly and is primarily an ion channel and not a water channel
as are the other Aqps (Ikeda et al. 2002).  Aqp-5 has high specificity for nitrate
instead of water in renal collecting ducts.  Elevated levels of nitrate have been
reported to inhibit H+ -ATPase activity (Valles and Manacha 2000) and inhibition
of H+ -ATPase activity is associated with obstruction of kidney collecting ducts.
The microarray data indicated a 1.5 fold upregulation of Apq-5 and the real-time
RT-PCR validated the upregulation by showing close to a 2.25 fold increase in
expression when cells were treated with FGF-23 compared to control conditions
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(Figure 20).  A standard curve not generated for this analysis.  However, the
absence of contamination as accessed by agarose gel electrophoresis and CT
values falling between 27.5 and 29.5 suggests that the analysis falls within the
linear range.  This data confirmed that FGF-23 induces expression of Aqp-5.
Figure 20.  Aquaporin 5 expression analysis of HK-2 cells treated with FGF-23 for 24 hours by
microarray and real-time RT-PCR.
 Real-time RT-PCR standard curves and amplification product
To demonstrate the reliability of the real-time RT-PCR analysis, a standard
curve was generated for each analyzed gene (with the exception  of aquaporin-5)
by diluting an oligo template representing the region amplified for each gene of
interest.  The oligo template served as a positive control for amplification product
and was used to establish a linear range of the SYBR green fluorescent intensity
that correlated to the double stranded PCR amplification product.  For each gene
analyzed, the threshold cycle (Ct) of all the RNA samples are between the highest
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and lowest template control (Figures 21-28).  The zero template negative control
yielded a value near or at 40 Ct corresponding to no double stranded DNA.  Some
of the PCR primers generated a primer dimer amplicon but by measuring the Ct at
higher temperatures, the short amplicon disassociates producing no signal while
the larger amplicon remains double stranded and produces a fluorescent signal
(FRP-4, mucin-2 and PTHr-2).  Figure 21 is the real-time RT-PCR amplification
data for FRP-4.  Figure 22 is the real-time RT-PCR amplification data for
1aOHase.  Figure 23 is the real-time RT-PCR amplification data for Adenomatosis
polyposis coli (APC).  Figure 24 is the real-time RT-PCR amplification data for 24-
OHase.  Figure 25 is the real-time RT-PCR amplification data for mucin-2.  Figure
26 is the real-time RT-PCR amplification data for parathyroid hormone receptor-2
(PTHr-2).  Figure 27 is the real-time RT-PCR amplification data for GAPDH by
HK-2 24 hour RNA dilution.  Figure 28 is the real-time RT-PCR amplification data
for GAPDH by Caco-2 24 hour RNA dilution.  Figure 29 is the real-time RT-PCR
amplification data for Aquaporin 5 RT-PCR amplification of HK-2 cells.  These
results confirm that each real-time RT-PCR analysis was performed within the
linear range of the assay.  In addition, a portion of amplicon produced by each
real-time RT-PCR reaction was assessed by gel-electrophoresis.  Each amplicon
was consisted with the expected size and no additional bands were observed in
negative controls or experimental samples (Figure 21b-28b, figure 29).  When
amplicons are observed in the negative control lane, they are a result of primer
dimer formation and are smaller in size than the expected amplicon sized.
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Although dramatic changes are not measured by real-time RT-PCR
analysis, the observed changes in expression for the genes selected to be
validated via RT-PCR generally paralleled the microarray results.  Genes that
were found to be induced across replicate experiments within a single cell type
(HK-2)(aquaporin 5) or across all three cell types (mucin-2) were validated by
real-time RT-PCR analysis whereas genes (i.e. PTHr-2 and FRP-4) that were not
observed to be consistently regulated across replicate array experiments were not
validated.  Real-time RT-PCR analysis validated genes found to be induced in
HK-2 cells (AQP-5 and mucin-2) and Caco-2 cells (1aOHase).  This indicates that
FGF-23 did induce a biological response in HK-2 and Caco-2 cells but a less
robust response was measured than anticipated (summarized in table 14).   Due
to limited amounts of RNA, Saos-2 samples were not validated via real-time RT-
PCR.  Therefore, these results cannot confirm whether these cells truly responded
to FGF-23.
Table 14.  Fold expression of house keeping genes spotted on the custom microarray.
Microarray Data RT-PCR Data
Cell type and time point Gene name Fold expression normalized to
GAPDH
Consistent
expression
Caco-2 24 hr 24-OHase 2.07 1.43 similar
Caco-2 24 hr 1AlphaOHase LS 2.23 No data
HK-2 24 hr 1AlphaOHase LS 1.56 No data
HK-2 24 hr PTHr-2 7.65 1.33 similar
Caco-2 24 hr APC 0.66 0.66 yes
HK-2 24 hr APC 0.49 0.67 yes
Caco-2 24 hr FRP-4 0.75 1.69 no
100ng HK-2 24 hr Mucin-2 3.20 1.61 yes
400ng HK-2 24 hr Mucin-2 3.20 1.76 yes
HK-2 24 hr AQP-5 2.20 2.27 yes
Caco-2 72 hr SSTR-3 1.80 1.73 yes
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Figure 21.  A. Standard curve of FRP-4 template versus threshold cycle (Ct) as determined by
real-time RT-PCR analysis.  B. Table representation of Ct values and standard deviation.  C.
Ethidium bromide stained 3% agarose gel template, sample, and zero template control.
Figure 21 A.
Figure 21 B.
Sample type and
template
average Ct Ct STDev
Caco 24 hr FGF 22.1 0.17
Caco 24 hr Neg 22.5 0.36
FRP-4 zero 39.0 0.16
FRP-4 1pM STD 21.2 0.13
FRP-4 10 fM STD 24.5 0.26
FRP-4 1 fM STD 24.8 0.08
FRP-4 100 aM STD 26.4 0.07
FRP-4 10aM STD 27.0 0.11
FRP-4 1 aM STD 29.7 0.04
Figure 21 C.
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Figure 22. A. Standard curve of 1aOHase template versus threshold cycle (Ct) as determined by
real-time RT-PCR analysis. B. Table representation of Ct values and standard deviation.  C.
Ethidium bromide stained 3% agarose gel template, sample, and zero template control.
Figure 22 A.
Figure 22 B.
Sample type and template average Ct Ct Stdev
Caco 24 hr FGF 26.5 0.27
Caco 24 hr Neg 27.1 0.09
HK-2 24 hr FGF 28.3 0.07
HK-2 24 hr Neg 29.0 0.20
1aOHase zero 40.0 0.00
1aOHase 1 pM STD 19.4 1.02
1aOHase 1 aM STD 34.8 1.89
1aOHase.01 aM STD 39.5 0.95
Figure 22 C.
25-alpha-1-hydroxylase standard curve
y = -1.0973Ln(x) + 27.01
R2 = 0.9995
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Figure 23. A. Standard curve of Adenomatosis polyposis coli (APC) template versus threshold
cycle (Ct) as determined by real-time RT-PCR analysis. B. Table representation of Ct values and
standard deviation.  C. Ethidium bromide stained 3% agarose gel template, sample, and zero
template control.
Figure 23 A.
Figure 23 B.
Sample type and template average Ct Ct Stdev
Caco 24 hr FGF 23.7 0.38
Caco 24 hr Neg 23.3 0.23
APC zero 40.0 0.00
APC 1 pM STD 16.6 0.17
APC 100 fM STD 23.5 0.51
APC 10 fM STD 27.3 0.80
APC 1 fM STD 31.8 1.14
APC 100 aM STD 34.7 1.12
Figure 23 C.
Adenomatosis polyposis coli (APC) standard curve
y = -1.9338Ln(x) + 31.251
R2 = 0.9773
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Figure 24. A. Standard curve of 24OHase template versus threshold cycle (Ct) as determined by
real-time RT-PCR analysis. B. Table representation of Ct values and standard deviation.  C.
Ethidium bromide stained 3% agarose gel template, sample, and zero template control.
Figure 24 A.
Figure 24 B.
Sample type and template average Ct Ct Stdev
Caco 24 hr FGF 28.6 0.16
Caco 24 hr Neg 28.3 0.13
24OHase zero 39.9 0.17
24OHase 10 fM STD 15.8 0.08
24OHase 100 aM STD 19.4 0.68
24OHase 1 aM STD 33.8 1.54
Figure 24 C.
24-hydroxylase standard curve
y = -1.954Ln(x) + 18.495
R2 = 0.8928
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Figure 25. A. Standard curve of mucin-2 template versus threshold cycle (Ct) as determined by
real-time RT-PCR analysis.  B. Table representation of Ct values and standard deviation.  C.
Ethidium bromide stained 3% agarose gel template, sample, and zero template control.
Figure 25 A.
Figure 25 B.
Sample type and template average Ct Ct Stdev
HK-2 24 hr FGF 25.5 0.12
HK-2 24 hr Neg 26.4 0.26
M-2 zero 39.0 1.68
mucin-2 5 pM STD 20.5 0.25
mucin-2 50 fM STD 24.3 0.15
mucin-2 5 fM STD 27.1 0.04
mucin-2 500 aM STD 31.2 0.23
Figure 25 C.
Mucin-2 standard curve
y = -1.1197Ln(x) + 29.493
R2 = 0.9637
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Figure 26. A. Standard curve of parathyroid hormone receptor-2 (PTHr-2) template versus
threshold cycle (Ct) as determined by real-time RT-PCR analysis. B. Table representation of Ct
values and standard deviation.  C. Ethidium  bromide stained 3% agarose gel template, sample,
and zero template control.
Figure 26 A.
Figure 26 B.
Sample type and template average Ct Ct Stdev
HK-2 24 hr FGF 24.8 0.50
HK-2 24 hr Neg 25.2 0.27
PTHr-2 zero 39.4 1.11
PTHr-2 5 pM STD 21.9 0.18
PTHr-2 500 fM STD 24.1 0.68
PTHr-2 50 fM STD 25.8 0.63
PTHr-2 5 fM STD 25.8 0.60
Figure 26 C.
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Figure 27. A. HK-2 24 hour RNA dilution for GAPDH expression analysis versus threshold cycle
(Ct) as determined by real-time RT-PCR analysis.  B. Table representation of Ct values and
standard deviation.  C. Ethidium bromide stained 3% agarose gel sample and zero template
control.
Figure 27 A.
Figure 27 B.
Sample type and RNA conc. average Ct Ct Stdev
GAPDH HK-2 24 hr FGF 10 ng 26.0 0.19
GAPDH HK-2 24 hr Neg 10 ng 26.2 0.41
GAPDH zero 40.0 0.00
GAPDH HK-2 FGF 24 hr 25 ng 25.8 0.28
GAPDH HK-2 FGF 24 hr 5 ng 27.7 0.50
Figure 27 C.
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Figure 28. A. Caco-2 24 hour RNA dilution for GAPDH expression analysis versus threshold cycle
(Ct) as determined by real-time RT-PCR analysis.  B. Table representation of Ct values and
standard deviation.  C. Ethidium bromide stained 3% agarose gel sample and zero template
control.
Figure 28 A.
Figure 28 B.
Sample type and RNA conc. average Ct Ct Stdev
Caco 24 hr 10 ng FGF 21.7 0.30
Caco 24 hr 10 ng Neg 22.1 0.06
GAPDH zero 40.0 0.00
GAPDH Caco 24hr 50 ng 17.6 0.11
GAPDH Caco FGF 24 25 ng 20.5 0.16
GAPDH Caco FGF 24 5 ng 22.0 0.17
Figure 28 C.
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Figure 29 shows the amplification of a single band by aquaporin 5 primers for the
HK-2 24 hour RNA sample as a template in lane 3. Lane 4 is a template free
negative control to demonstrate that the reaction is contamination free.
Figure 29. Ethidium bromide stained 3% agarose gel of Aquaporin 5 RT-PCR amplification of HK-
2 cells treated with FGF-23 for 24 hours and zero template control.
Aquaporin 5 ethidium bromide gel
Lane 1: 2 mg 100 bp ladder.
Lane 2: blank
Lane 3: HK-2 24 hr FGF Apr-5
Lane 4: Aqp-5 zero template
Lane  1,   2,   3,    4,
600 bp
100 bp
300 bp
200 bp
500 bp
400 bp
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Expression levels of house keeping genes were measured on the custom
microarray. The RT-PCR data described above was normalized to GAPDH for
HK-2 and Caco-2 cells measured at 24 hours. Similar to the real-time RT-PCR
data (figure 27b, 28b) custom microarray data (table 15), no significant change in
mRNA expression was observed for FGF-23 treated and control cells.
Table 15.  Fold expression of house keeping genes spotted on the custom microarray.
Low Signal intensity(LS) caco HK-2 Saos
EF-1 NM_001959 24hr 0.80 LS LS
72hr LS LS LS
beta-Actin AF111848 24hr 0.82 0.83 LS
72hr LS LS LS
alpha Tubulin NM_006082 24hr 1.26 1.25 0.60
72hr 1.47 15.26 0.98
Cyclophilin-A NM_021130 24hr 1.18 1.26 0.98
72hr 1.12 11.06 0.84
GAPDH NM_002046 24hr 1.08 1.07 0.87
72hr 1.05 5.16 0.96
STAT1 NM_007315 24hr LS LS LS
72hr LS LS LS
beta-glucuronidase NM_000181 24hr LS LS LS
72hr LS LS LS
107
DISCUSSION
RT-PCR receptor profiling
In vitro binding studies by Yamashita et al.  (2002) and Pragnell
(unpublished) indicate that FGF-23 binds to FGF receptors 2, 3 and 4.  To
determine the possibility of FGF-23 acting on selected cell lines, RT-PCR analysis
was conducted for FGF receptor gene expression.  Several cell lines predicted to
play a role in phosphate uptake were screened for gene expression.  Previously
validated GAPDH PCR primers were used as a positive control, and reactions
without the addition of reverse transcriptase (RT) demonstrated that there were no
detectable levels of genomic contamination when no bands were visualized in the
RT omitted control lanes.  The PCR amplification products were of the expected
size and migrated correctly in comparison to each other based on the positioning
of the designed primers.  The RT-PCR receptor profiling of Caco-2, HK-2, and
SaOS-2 cells demonstrate that of all three FGF receptors believed to be relevant
to FGF-23 signal are expressed.  This result indicates that FGF-23 may be
capable of inducing a biological response in model cell lines selected to represent
sites of phosphate regulation.  However, amplification of correct sized amplicons
only indicates gene expression, but does not ensure proper translation,
localization, availability/accessibility, and protein stability to ensure the receptor is
available for ligand signaling.  In addition to these variables, it is also possible that
additional, yet to be identified, novel receptor(s) may be involved in FGF-23
signaling and the cell specific expression of that receptor is subsequently
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unknown.  To our best knowledge, the receptors required for FGF-23 signaling
are present in the target cell lines used in these experiments.
Furthermore, Saos-2 and HK-2 cells were tested to respond to FGF-23
treatment by a phosphate uptake assay (Bowe, Genzyme Corp) (Appendix figure
33).  A 40% phosphate uptake inhibition was observed in both cell lines (Appendix
figure 32b).  Saos-2 and HK-2 cells were also tested for biological response to
FGF-23 by increased tyrosine phosphorylation of receptor related signaling.  Both
cell lines showed an increased phosphorylation when treated with FGF-23
compared to control (O’Brien, Genzyme Corp, Data not shown).  Caco-2 cells
were tested once for a response to FGF-23 treatment by phosphate uptake.
Caco-2 cells did not demonstrate an inhibition of phosphate uptake when treated
with FGF-23 (data not shown).
Biological relevance of identified genes
Examination of protein function of genes suggested to be differentially
regulated by array analysis revealed multiple cellular functions that may be
regulated by FGF-23.  The majority of the identified expression changes fell into
six general classifications.  These categories were the following: general cell
change, differentiation, division, membrane channels and transporters, metabolic
enzymes, and unknown functions.  Most of the upregulated genes are associated
with cell growth, differentiation, and various cellular changes.  Table 9, of the
results section, shows apparent upregulation of genes such as glutathione S-
transferase theta 2 and hyaluronoglucosaminidase 1, which are required for anti-
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apoptotic activity and enhanced cellular growth.  The downregulated genes are
also involved in similar cellular function but with an opposite function.  Table 10
shows genes like TNFRSF6, required for apoptosis to be down regulated and
other genes involved in stress and immune responses.  In general, the cells
viability did not seem to be compromised based on the observed genes that
appeared to be differentially expressed with FGF-23 treatment.
The three cell types appeared to respond to FGF-23 by modulating various
transcription factors, receptors, and membrane channels/transporters.  The HK-2
cell line, which is of kidney epithelial origin and the Caco-2 cell line, which is
derived from a small intestine epithelial cells, had more common genes induced
than SaOS-2 cells.  Several genes associated with calcium and/or phosphate
regulation were similarly modulated in the HK-2 and Caco-2 cell lines.  Table 6 of
the result section highlights some of these genes.  This finding is not surprising in
that the intestinal and renal cell lines are both of epithelial origin and are derived
from tissues whose main functions are to regulate transport of metabolites.  The
SaOS-2 cell line is osteoblast-like, of mesenchymal origin, and represents a tissue
with distinct functions compared to epithelial cells.
The commercial arrays provided an opportunity to survey multiple genes
without bias to obtain a basic understanding of FGF-23 actions.  The observation
that most potentially regulated genes have generalized functions related to cell
changes suggests that in addition to control of phosphate homeostasis, FGF-23
might play a role during embryogenesis, development and/or differentiation of
specific cell types.  Additional studies will be required to confirm this hypothesis.
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The custom array approach was an opportunity to ask specialized
questions regarding specific genes whose functions might be related to the known
functions of FGF-23.  Significant emphasis was placed on selection of appropriate
genes through review of the literature.  The observation that two-thirds of the
oligos spotted had signals representing general expression of selected genes
confirmed and established this approach.  These arrays will form the basis of
further analysis and can be expanded using gene candidates identified through
the commercial arrays.
Data from the custom microarray analysis suggested that several genes
identified through OOM SAGE analysis were regulated by FGF-23 (table 12 and
13).  This result supported the hypothesis that some OOM associated genes
represent genes whose expression was induced by the autocrine actions of FGF-
23.  The expectation was that most differentially regulated genes would have
been upregulated but many OOM genes appeared to be downregulated by FGF-
23.  Given that a single experiment was performed for each cell condition, this
discrepancy may reflect a high number of false negatives.
Additionally, several human homologues to yeast phosphate related genes
were also identified to be differentially expressed (Table 13 and 14).  A phosphate
regulated pathway has been well studied in yeast yet little is known regarding a
similar pathway in mammalian cell types.  However, multiple human homologues
of yeast proteins within this pathway have been identified (Dong Yu, Genzyme
Corp.).  These homologues were spotted on the custom microarray to determine if
FGF-23 may influence expression of genes.  Cathepsin D precursor was seen to
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be upregulated 4 fold, while pituitary homeobox 1 and sodium dependant high-
affinity dicarboxylate transporter was down regulated 2.5 fold.  Although the signal
intensity for each gene on the custom microarray is an average of four spots, it is
still a single microarray analysis and would require replicate analysis from multiple
samples and real-time RT-PCR validation before the fold changes could be
considered to be statistically significant.  The sodium-dependant high-affinity
dicarboxylate transporter produced the greatest signal in both FGF-23 treated and
control cell RNA samples, making the fold induction more reliable.  Future work
should monitor FGF-23 induced repression via real-time RT-PCR of the sodium
dependent high-affinity dicarboxylate transporter.
FGF-23 appears to regulate two key genes of the Wnt signaling pathway
by microarray analysis.  By microarray analysis, FGF-23 reduced adenomatosis
polyposis coli (APC) expression 1.5 fold in both HK-2 and Caco-2 cells at 24
hours.  Real-time RT-PCR analysis showed a similar weak down regulation in
Caco-2 cells at 24 hours.  Additionally, Beta catenin-1 was upregulated at 72
hours in both cell types, but RT-PCR validation was not conducted on beta
catenin-1.  These two genes are known to be integral components of the Wnt
signaling pathway (Slusarski et al. 1997).  When the Wnt signaling pathway is
inactive, APC is a key component in the pathway responsible for beta-catenin
degradation.  The degradation of beta-catenin results in WNT signaling inhibition.
Upon Wnt activation, APC disassociates from beta-catenin so beta-catenin is not
degraded and is allowed to enter the cell nucleus for transcriptional activation of
several oncogenes and cellular growth genes (figure 30).  There is no evidence
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that directly links the Wnt signaling pathways to calcium or phosphate regulation.
However, some FRPs are known to modulate Wnt signaling (Jones and Jomary
2002, Bergwitz et al. 2001, Jones and Jomary 2002, Robitaille et al. 2002).
Based on homology between the phosphatonin, FRP-4 and other FRP family
members, it is reasonable to speculate that FRP-4 might also interact with the
Wnt signaling pathway.  It is difficult to assert the specific biological significance of
the FGF-23 induced down regulation of APC and the upregulation of Beta-catenin
but it is possible that this may activate the Wnt pathway resulting in subsequent
gene transcription.  The potential down-regulation of FRP-4 observed by
microarray analysis was not validated by real-time RT-PCR analysis.  However,
the concept that FGF-23 might regulate FRP-4 expression and WNT pathway
members is intriguing.  Relationships between Wnt and FGF pathways have
already been established in development systems (Jones et al. 2002).    Clearly
additional and quantitative studies will be required to understand this potential
relationship.
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Figure 30.  Generalized Wnt/b-Catenin signaling pathway  (Slusarski et al. 1997).  Upon Wnt
binding to membrane bound frizzled, APC disassociates from Beta-catenin allowing for entry into
the cell nucleus and transcription of various genes related to growth.  Down regulation of APC and
up regulation of Beta-catenin by FGF-23 may have a similar activating function.  FRPs (Frzb) are
known to inhibit Wnt signaling.
PTH receptor
Parathyroid hormone receptor -1 (PTHr-1, NM_000316) and PTHr-2
(NM_005048) appeared to be upregulated by FGF-23 by microarray analysis.
However, real-time RT-PCR analysis of PTHr-2 showed no change in expression.
Expression of PTHr-1 was not tested by real-time RT-PCR but microarray
analysis suggested a potential 2.1 fold increase in HK-2 cells at 24 hours post
FGF-23 treatment.  PTHr-1 is most abundantly expressed in the kidney, bone,
By microarray analysis, FGF-23
downregulates at 72 hours
FGF-23 downregulates at 24 hours.
By microarray analysis, FGF-23
upregulates at 72 hours.
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and liver.  Mutations in PTHr-1 are associated with murk-jansen and blomstrand
type of abnormal bone growth.  Clinical symptoms of these two types of
chondrodysplasia are a rare form of short limb dwarfism associated with
hypercalcemia and low to normal levels of the two parathyroid hormones.  Since
PTHr-1 and PTHr-2 both bind the parathyroid hormone that is the primary method
of calcium homeostasis, it would be valuable as a future experiment to validate
the increased expression level of PTHr-1 in the HK-2 cells by real-time RT-PCR.
1-alpha-hydroxylase and 24-hydroxylase
As depicted in figure 31, in response to low serum calcium levels, PTH
elevates active vitamin D levels which subsequently causes an increase in
calcium serum levels, and also induces phosphate wasting through the kidney by
reducing the reabsorption rate.  The production of active vitamin D is achieved
through 1aOHase activity in the kidney.  Although 1aOHase expression levels
were below the lower limit of detection of the microarrays, a 2 fold increase was
measured by real-time RT-PCR analysis of the Caco-2 cells at 24 hours.  A slight
but non-significant increase was detected in the HK-2 cells measured at the 24
hour time point.  No other conditions were tested for 1aOHase expression via
real-time RT-PCR.  These results are contradictory to 1aOHase expression levels
observed in the in vivo mouse kidney studies (Shidmada et al. 2002).  Several
reasons may explain why 1aOHase was observed to be induced in Caco-2 cells
by real-time RT-PCR and a non-significant response was observed in HK-2 and
Saos-2 cells.  The first and most significant difference is that 1aOHase was down
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regulated in vivo where additional factors are present that may be required for
1aOHase mRNA levels to be affected such as the presence of heparin, vitamin D
and/or other yet to be discovered factors.  Currently there are no human renal cell
lines known to respond to FGF-23 by a change in 1aOHase mRNA levels and
currently the best model to validate FGF-23 biological activity by measuring
phosphate uptake is using an opossum cell line and not a human cell line.
Second, 1aOHase was observed to be affected within the in vivo experiments
within 1 hour and maximal reduction of 1,25(OH)2D3 was seen between 8-13
hours, suggesting that 1aOHase and/or 24-hydroxlase maybe modulated prior to
the 24 hour time point at which mRNA levels were measured in our experiment.  It
is possible that 1aOHase was regulated in a similar manner as in the in vivo
studies but a non-optimal time point was selected to observe this response.  The
24 hour time point was selected to measure a sustained FGF-23 exposure
response and not to measure initial transcriptional genes that may be indicative of
general growth factors and not necessarily specific to FGF-23.  It is also possible
that FGF-23 plays a different role in controlling 1,25(OH)2D3 production in
intestinal tissue compared to renal tissues.  The bulk of circulating 1,25(OH)2D3 is
believed to be produced in the kidney and levels of 1aOHase are significantly
greater in renal versus intestinal tissues.  It is possible that differential regulation
at the intestine might result in local changes in 1,25(OH)2D3 rather than systemic.
Additionally, no significant transcriptional changes to 24-OHase, the
enzyme that degrades active vitamin D, was observed by real-time RT-PCR
analysis in Caco-2 cells at 24 hours.  This real-time RT-PCR result conflicts with
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the microarray results where a two fold expression was observed in the Caco-2 24
hour time point cell sample.
There are indications that the Caco-2 cells responded to FGF-23 treatment
at 24 hours with an increase in 1aOHase mRNA but with a non-significant change
in 24-OHase.  It is likely that there is an accumulation of active vitamin D but to be
certain 1,25-dihydroxyvitamin D3 would have to be directly measured.
1aOHase is expressed in a wide variety of cells including renal, monocytes, skin
cells (Holick 1999) and intestine (Zehnder et al. 2001).
Figure 31.  Known effect of PTH in response to low serum calcium levels.  An increase in
1aOHase increases active vitamin D (1,25OH2D3) levels.
Somatostatin receptors
The somatostatin hormone is distributed throughout the body.
There are two primary forms of somatostatin, somatostatin –14 and somatostatin
–28.  These two forms of somatostatin bind to five known somatostatin receptors
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(SSTr) that are involved in a variety of important endocrine and nervous system
regulatory functions.
Several of the somatostatin receptors (SSTR) were observed to be
potentially differentially expressed in HK-2 and Caco-2 cells treated with FGF-23.
Of the five known SSTRs, SSTR1-4 appeared to be upregulated at various time
points.  Of particular interest is the apparent up regulation of SSTR-2 at 72 hours
in both HK-2 and SaOS-2 cells.  SSTR-2 is expressed in the brain, kidney,
intestine, liver and is a marker for oncogenic osteomalacia tumors (Jan de Beur et
al. 2002b), which as previously discussed, over express FGF-23 and induce
phosphate wasting.  Although the specific binding and signaling interaction of the
two forms of SST to the five SSTRs is not completely understood, SSTR-2
expression and signaling has been associated with a rapid increase in intracellular
calcium levels and availability of phosphate (Rosskopf et al. 2002).  SSTR-2 was
observed to be upregulated 1.7 fold by microarray analysis and 1.8 fold by real-
time RT-PCR analysis.  A standard curve was not generated for this gene, hence
the results are presented in the appendix section.
Aquaporins
Aquaporins (Aqp) are a family of extracellular membrane bound water
channels expressed in various organs.  Aqp-5 and Aqp-6 appeared to be
upregulated in HK-2 cells by microarray analysis.  Aqp-5 was seen to be
potentially upregulated 2 fold in HK-2 cells at 24 hours by both microarray and
real-time RT-PCR analysis (Figure 20).  Reabsorption in the kidney's proximal
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tubules involves Aqp-2 and 3, which are not observed to be modulated by FGF-
23.
Although Aqp-6 was also suggested to be upregulated by FGF-23 in HK-2
cells by microarray analysis, real-time RT-PCR validation was inconclusive due to
a high amount of non-specific RT-PCR amplification (appendix figure 2).  Although
Aqp-6 is structurally similar to the other family members, it is unique because it is
expressed intracellularly and is primarily an ion channel and not a water channel
as are the other Aqps (Ikeda et al. 2002).  Even though the residues critical for
water transport are highly conserved with only few changes, Aqp-6 has high
specificity for nitrate instead of water in renal collecting ducts.  Elevated levels of
nitrate have been reported to inhibit H+ -ATPase activity (Valles and Manucha
2000) and inhibition of H+ -ATPase activity is associated with obstruction of kidney
collecting ducts.
Custom microarray
Of the 205 genes spotted on the custom array, 87 genes produced a signal
intensity less than 500 units under all conditions tested and 64 genes produced a
signal intensity less than 300 units.  Table 1 of the appendix section contains a list
of these genes.  Several reasons may explain why 30 percent of the genes
produced a signal at or below the sensitivity of the microarray.  Many of the gene
families such as bone morphogenic proteins (BMPs), matrix metalloproteinase
(MMPs), TRAILR and many others, may only be expressed under specific bone
differentiated states and would not be expected to be expressed by the cells
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under the conditions tested.  Additionally, these genes and their sequences are
available in the publicly available gene databases such as National Center for
Biotechnology Information (NCBI) yet many were not spotted on the Clontech
commercial microarray.  It is possible that these genes possess a unique
secondary structure that makes the design of efficient hybridization probes more
difficult and were not included in the commercial microarray because they failed
the extensive quality control tests.
Seven house keeping genes were selected to be placed on the custom
microarray.  STAT1 and beta-glucronidase always produced a signal intensity less
than 500 units of fluorescence.  An approximate 1.5 fold change in expression
was observed for alpha tubulin in Saos-2 72 hour and HK-2 72 hour, Cyclophilin-A
HK-2 72 hour, and GAPDH HK-2 72 hour.  Analysis of HK-2 72 hour sample by
real-time RT-PCR did not verify any significant change (table 12).
Summary
In conclusion, microarray analysis suggests that all three cell lines
representing the three known sites of phosphate regulation may be responded to
FGF-23 treatment but the FGF-23 induced mRNA expression response was
weaker than expected.  Genes involved in the Wnt signaling pathway, parathyroid
receptor signaling, somatostatin receptor signaling, and aquaporin channels were
among the genes modulated by FGF-23.  A more robust and similar response
was observed in HK-2 and Caco-2 cells than in SaOS-2 cells.  For rapid
modulation of phosphate or calcium, similar mechanisms could be used to block
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intestinal mineral absorption and renal reabsorption to lower serum levels or
enhance transport to elevate serum levels.  Both these sites require a
monodirectional transport and the transport rate is modulated to maintain serum
homeostasis.  The SaOS-2 cells, representing bone, may not have been in the
optimal bone differentiation state to best respond to FGF-23, and phosphate
regulation may be modulated through an alternative pathway.  It is likely that
phosphate transport is achieved in different tissues using distinct methods
because the primary renal phosphate transporter is NaPi2a, while GLVR-1 is the
primary bone phosphate transporter.
In general, few genes were observed to be drastically affected by FGF-23
treatment across the three cell types.  The purified FGF-23 used in these
microarray studies was demonstrated to be biologically active by an opossum
kidney cell phosphate uptake assay (A. Bowe, Genzyme Corp.).  All cell types
tested appeared to respond to FGF-23 treatment, but the measure of potency by
microarray and, in particular, real-time RT-PCR was less than expected.  Although
a dampening of relative induction levels obtained by array analysis is well
established, more robust and reliable inductions are typically observed using real
time RT-PCR.  There are several factors that may have contributed to the non-
potent response.  Various forms of heparin may affect the binding specificity of
FGF-23.  The effect of heparin on FGF-23 binding to FGF receptors is currently
being studied to better understand the role of heparin on ligand/receptor binding
to potentially help optimize FGF-23 potency.  The half-life of FGF-23 may vary
when exposed to different cell types.  The optimal window to measure mRNA
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responses to FGF-23 treatment may have been missed.  Further in vitro and in
vivo studies will help to better understand the stability of FGF-23.  The cell types
treated with FGF-23 may not have been in the optimal cell cycle or differentiated
state to best respond to FGF-23 treatment.  A non-homogenous cell population
within one culture may have caused some cells to be less responsive, thereby
masking the FGF-23 induced transcriptional response and hence the mRNA
levels measured by the microarray and real-time RT-PCR.  Monitoring mouse in
vivo and/or in situ expression levels of the genes identified in this study, as well as
additional microarray analysis of RNA isolated from tissue samples may provide
insight into the complex regulation of phosphate as affected by FGF-23.
One caveat of this study that may have influenced the relative fold-
induction observed by real-time RT-PCR is the choice of genes selected for
analysis and the fact that most genes were not selected based on statistical
analysis of repeat experiments with multiple biological samples.  Assuming this
was done, the expectation is that some genes would be identified that were
induced to a greater degree and consistently by FGF-23.
In conclusion, HK-2 and Caco-2 cells responded to FGF-23 treatment by
modulating mRNA expression as measured by microarray and real-time RT-PCR
analysis.  FGF-23 may have also induced changes in gene expression as
measured by microarray analysis but fewer genes in Saos-2 cells were affected
than HK-2 or Caco-2 cells.  Since real-time RT-PCR validation was not
conducted on Saos-2 cell mRNA, it can not be determined whether the genes
observed by microarray analysis are truly modulated genes.   Additionally the
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limited number of biological and technical replicates limit the statistical certainty of
the currently identified genes.  Future in vitro experiments should include real-time
RT-PCR measurement of 1aOHase and consistently modulated genes like mucin-
2 and aquaporin family members in a time course experiment.  This may lead to
the identification of a more optimal time point to identify FGF-23 induced mRNA
expression.  The selected time point should be tested by biological and technical
replicates.  Alternatively, in vivo tissue mRNA studies of mice treated with FGF-23
may provide a more accurate model for the biological function of FGF-23 where
yet to be identified additional factors required for signaling are present as
validated by the observed phosphate wasting.
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APPENDIX
Figure 32a.  Opossum kidney phosphate uptake assay demonstrated the biological activity of
FGF-23 used in all microarray experiments.  (Bowe, Genzyme Corp.)
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Figure 32b.  Phosphate uptake assay demonstrates biological response of
Saos-2 and HK-2 to FGF-23 treatment. (Bowe, Genzyme Corp.)
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Figure 33.  Real-time RT-PCR analysis without standard curve and without ethidium bromide gel
analysis.
Figure 34.  Ethidium bromide gel of Aquaporin 5 and 6 RT-PCR amplification. Non-specific
amplification is seen for Aquaporin 6 and primer dimer formation in the negative control.
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Table 16. List of genes spotted on the custom microarray but expressed a signal intensity less
than 500 unit in all conditions tested.  * Gene signal intensity greater than 300 units but less than
500 units.
accession gene name
NM_000181 beta-Glucronidase
NM_015675 growth arrest and DNA-damage-inducible, beta
AK023607 Homo sapiens cDNA FLJ13545 fis, clone
PLACE1006867
NM_002838 LCA protein tyrosine phosphatase, receptor type, C
AK024230* 14-3-3 gamma
AL031228 a2-Collagen Type XI
NM_001148 ANK2_HUMAN  Ankyrin 2
NM_017680 Asporin
NM_004324 Bax
NM_020396 BCL2-like 10 (apoptosis facilitator)
AF111848* beta-Actin
NM_033637 beta-trcp
NM_005811 bone morphogenetic protein 11 (BMP11)
NM_001200 Bone morphogenetic protein 2 (BMP2)
NM_001201 Bone morphogenetic protein 3 (BMP3)
NM_001719 Bone morphogenetic protein 7 (osteogenic protein 1)
NM_004967 Bone Sialo protein (BSP)
NM_004348 CBFA1/RUNX2
NM_001798* CDK2_HUMAN Cell division protein kinase 2
NM_003465* chitinase 1
NM_001892 ck1 (casein kinase 1)
NM_001895* ck2 (casein kinase 2)
NM_001854 collagen 11
NM_001850 collagen 8 alpha1
NM_000493 collagen type IX
NM_000493 Collagen Type X
NM_003254* collagenase inhibitor mRNA/TIMP-1
NM_001901 Connective Tissue Growth Factor
NM_000962 Cox1
NM_003649 D-aspartate oxidase variant 1
NM_001920 DCN
NM_005221 Dlx5
NM_001959* EF-1
NM_016357 epithelial protein lost in neoplasm beta
NM_058229 EST
NM_024732 EST AA625899
NM_022450* EST(hypothetical protein FLJ22357 similar to
epidermal growth factor receptor-related  protein)
AJ420488 eukaryotic translation elongation factor 1 alpha 1
AF298880 Exportin 5
NM_005117 FGF-19
NM_000138 fibrillin 1
NM_001999 fibrillin 2
NM_002021 Flavin containing monooxygenase 1
NM_006894 Flavin containing monooxygenase 3
NM_005479 frat-1
NM_000557 GDF5
NM_001537 heat shock factor binding protein 1
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NM_002856* HVEB mRNA
AK022929* hydroxysteroid (17-beta) dehydrogenase 7
NM_000619 IFN gamma
NM_000600 IL-6
NM_007315* ISGF-3 (STAT1)
NM_005354* JunD
NM_020196 KIAA 1177 protein
U50748 leptin receptor
NM_002427 matrix metalloproteinase 13(MMP13)
NM_004995 matrix metalloproteinase 14 (MMP14)
NM_004530* matrix metalloproteinase 2 (MMP2 )
NM_004994 matrix metalloproteinase 9 (MMP 9)
NM_020203* MEPE
NM_000900 MGP (matrix gla protein)
NM_024165* milk PDH finger protein 1
NM_002449 Msx-2
NM_004897 Multiple inositol polyphosphate phosphatase
NM_005074 Napi1 (SLC17A1)
NM_003052* Napi2a
NM_013436* Nck-associate protein 1
NM_005450 Noggin
NM_003058 Organic cation transporter
NM_004418* PAC-1(protein tyrosine phosphatase)
BC008826* Paired box gene 3 (Waardenburg syndrome 1) PAX-3
NM_002609 PDGF-BB
NM_000444* PEX or PHEX
NM_002845 protein ty phosphatase rec type M
NM_002668 Proteolipid protein 2
NM_005048* PTH receptor 2
NM_002775* Serine Protease 11 (IGF Binding)
NM_001463 sFRP-3
NM_014474 Similar to acid sphingomyelinase-like
phosphodiesterase
NM_000627 TGFb Binding Protein
NM_000594 TNF
NM_003844 TRAILR-1
AF016266 TRAILR-2
NM_003841 TRAILR-3
NM_003840 TRAILR-4
NM_003287 tumor protein D52-like 1
AF089744 Xenotropic and polytropic murine retrovirus receptor
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